H. Charles Manning, Ph.D.
Department of Cancer Systems Imaging, Division of Diagnostic Imaging
Present Title & Affiliation
Primary Appointment
Director, Division of Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, Texas
Director (Joint appointment), Department of Cyclotron Radiochemistry Facility, The University of Texas MD Anderson Cancer Center, Houston, TX
Graduate Faculty, Department of Graduate School of Biomedical Sciences, The University of Texas Health Science Center, Houston, TX
Professor, Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX
Scientific Director (Joint appointment), Department of Center for Advanced Biomedical Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Director, The University of Texas MD Anderson Cancer Center, Houston, Texas
Director, Department of Cyclotron Radiochemistry Facility, The University of Texas MD Anderson Cancer Center, Houston, TX
Graduate Faculty, Department of Graduate School of Biomedical Sciences, The University of Texas Health Science Center, Houston, TX
Professor, Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX
Scientific Director, Department of Center for Advanced Biomedical Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Research objective: Development, validation, implementation, and clinical translation of imaging and chemical probes to non-invasively quantify molecular events in vivo.
Representative research key words: Precision imaging diagnostics; precision medicine; drug development; cellular metabolism; glutamine; molecular imaging biomarkers; oncology; neuroscience; cell signaling; proliferation; cell death; translocator protein; drug development; medicinal chemistry; high-throughout, small-molecule screening; treatment response; positron emission tomography (PET); single photon emission computed tomography (SPECT); radiochemistry; radiopharmaceuticals; theranostics; magnetic resonance imaging (MRI), cyclotron.
Education & Training
Degree-Granting Education
| 2004 | Texas Tech University, Lubbock, Texas, US, Ph.D. in Chemistry |
| 2000 | Tarleton State University, Stephenville, Texas, US, BS in Chemistry |
Postgraduate Training
| 2004-2006 | Research Fellowship, Vanderbilt University, Nashville, Tennessee |
Experience & Service
Faculty Academic Appointments
Vanderbilt Ingram Professor of Cancer Research, Department of Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TX, 2015 - 2020
Professor, Vanderbilt University - Chemistry, Nashville, TN, 2015 - 2020
Professor, Vanderbilt University - Biomedical Engineering, Nashville, TN, 2015 - 2020
Professor, Department of Neurosurgery, Vanderbilt University - Neurosurgery, Nashville, TN, 2015 - 2020
Professor of Radiology and Radiological Sciences with Tenure, Vanderbilt University, Nashville, TN, 2015 - 2020
Associate Professor, Department of Biomedical Engineering, Vanderbilt University, Nashville, TN, 2012 - 2015
Associate Professor of Radiology and Radiological Sciences with Tenure, Vanderbilt University, Nashville, TN, 2012 - 2015
Associate Professor, Vanderbilt University, Nashville, TN, 2012 - 2015
Assistant Professor of Radiology and Radiological Sciences with Tenure, Vanderbilt University, Nashville, TN, 2008 - 2012
Assistant Professor, Vanderbilt University, Nashville, TN, 2007 - 2012
Assistant Professor, Department of Neurosurgery, Vanderbilt University, Nashville, TN, 2006 - 2012
Research Assistant Professor, Vanderbilt University, Nashville, TN, 2006 - 2008
Other Professional Positions
Member, Academy for Radiology & Biomedical Imaging Research’s (The Academy), 2024 - Present
Board Member, Coalition of PET Drug Manufacturers, Houston, TX, 2023 - Present
Faculty Mentor, The University of Texas MD Anderson Cancer Center - TRIUMPH - Faculty Mentor - Postdoctoral Fellowship - CPRIT, Houston, TX, 2022 - Present
Mentor, The University of Texas MD Anderson Cancer Center Leadership Institute, Houston, TX, 2022 - Present
SAC - Scientific Advisory Committee Member, Vanderbilt University Medical Center, Nashville, TN, 2021 - 2024
External Advisory Committee Member, University of Texas RGV - Integrated Cancer Research Core (ICRC), Houston, TX, 2021 - Present
Senior Scientific Faculty Advisor, Vanderbilt University Medical Center Research Radiochemistry Core Laboratory and Cyclotron Resource, Nashville, TN, 2018 - 2020
Planning and Steering Committee, Vanderbilt University, Sixth Frontiers of Biomedical Imaging Science Conference, Nashville, TN, 2017 - 2018
Planning and Steering Committee, Vanderbilt University, Fifth Frontiers of Biomedical Imaging Science Conference, Nashville, TN, 2015 - 2016
Director, Cancer Imaging Research, Vanderbilt Ingram Cancer Center (VICC), Nashville, TN, 2015 - 2020
Planning and Steering Committee, Vanderbilt University, Fourth Frontiers of Biomedical Imaging Science Conference, Nashville, TN, 2013 - 2014
Founding Director, Vanderbilt Center for Molecular Probes, Nashville, 2013 - 2020
Member, Vanderbilt Institute of Chemical Biology (VICB), Nashville, TN, 2011 - 2020
Member, Vanderbilt Ingram Cancer Center (VICC) GI Program, Nashville, TN, 2011 - 2020
Project 1 Co-Leader, Vanderbilt University SPORE in GI Cancer, Nashville, TN, 2011 - 2017
Co-Leader, Vanderbilt University SPORE in GI Cancer, Translational Pathology and Imaging Core, Nashville, TN, 2011 - 2017
Planning and Steering Committee, Vanderbilt University, Third Frontiers of Biomedical Imaging Science Conference, Nashville, TN, 2011 - 2012
Scientific Director and Administrative Director, Vanderbilt University Medical Center Research Radiochemistry Core Laboratory and Cyclotron Resource, Nashville, TN, 2011 - 2018
Member, Vanderbilt University Radioactive Drug Research Committee (RDRC), Nashville, TN, 2011 - 2020
Member, Vanderbilt University Health Sciences Radiation Committee (HSRC), Nashville, TN, 2011 - 2016
PET Imaging Research Internal Advisory Board, Vanderbilt University Medical Center, Nashville, TN, 2010 - 2020
Co-Director, Preclinical Models of Digestive Disease Core, Vanderbilt Digestive Disease Research Center (VDDRC) Associate Director, Nashville, TN, 2010 - 2020
Member, Vanderbilt Digestive Disease Research Center (VDDRC), Nashville, TN, 2010 - 2020
Organization Committee Chair, Vanderbilt University Institute of Imaging Science (VUIIS) Research Retreat, Knoxville, TN, 2009 - 2010
Member, Host-Tumor Interaction Program, Vanderbilt Ingram Cancer Center (VICC), Nashville, TN, 2009 - 2011
Planning and Steering Committee, Vanderbilt University, Second Frontiers of Biomedical Imaging Science Conference, Nashville, TN, 2009 - 2010
Member, Planning and Steering Committee, Vanderbilt University, Inaugural Frontiers of Biomedical Imaging Science Conference, Nashville, TN, 2008 - 2009
Member, Vanderbilt Ingram Cancer Center (VICC), Nashville, TN, 2008 - 2020
Member, Vanderbilt Ingram Cancer Center (VICC) Experimental Therapeutics Program, Nashville, TN, 2008 - 2009
Faculty Director of Molecular Imaging Research, Vanderbilt University Institute of Imaging Science (VUIIS), Nashville, TN, 2008 - 2020
Co-Director, Vanderbilt University SPORE in Breast Cancer "Preclinical Imaging Core", Nashville, TN, 2008 - 2013
Program in Chemical and Physical Biology, Vanderbilt University, Nashville, TN, 2008 - 2020
Organization Committee Member, Vanderbilt University Institute of Imaging Science (VUIIS), Chattanooga, TN, 2008 - 2009
Organization Committee Member, Vanderbilt University Institute of Imaging Science (VUIIS) Research Retreat, Memphis, TN, 2006 - 2007
Faculty Director, Vanderbilt University Institute of Imaging Science (VUIIS), Nashville, TN, 2006 - 2008
Post-doctoral Research Fellow, Vanderbilt University, Institute of Imaging Science and Department of Radiology, Nashville, TN, 2004 - 2006
Graduate Student and Research Associate, Texas Tech University, Department of Chemistry and Biochemistry, Lubbock, TX, 2000 - 2004
Undergraduate Research Assistant, Tarleton State University, Department of Physical and Environmental Sciences, Stephenville, TX, 1996 - 2000
Institutional Committee Activities
Member, CNP Unit Steering Committee Introduction, 2024 - Present
Member, MD Anderson Cancer Neuroscience Program - FY24 CNP Proposal Review Panel, 2023 - Present
Member, DI Research Infrastructure Committee, 2022 - Present
Co-Chair, DI Research Infrastructure Education Subcommittee, 2022 - Present
Member, The University of Texas MD Anderson Cancer Center Institutional Radiation Safety Committee, 2022 - Present
Member, CSI Chemistry/Radiochemistry Committee, 2022 - Present
Associate Member, Steering Committee, Graduate Program in Medical Physics, 2022 - Present
Co-Lead, Research, MD Anderson Theranostics Program, 2021 - Present
Member, SAIF Steering Committee, 2021 - Present
Member, CABI Executive Steering Committee, 2021 - Present
Member, DI DEI - Diversity, Equity and Inclusion Committee, 2021 - 2023
Member, Image-Guided Cancer Therapy (IGCT) Research Program, 2021 - Present
Member, DI - Imaging Physics Dept - Radiological Physics Section Chief - Search Committee, 2020 - 2021
Member, DI - Research Functional Committee (DI-RFC), 2020 - Present
Member, DI - Innovations Task Force, 2020 - 2022
Member, DI - Clinical Operations Committee, 2020 - Present
Committee Chair, The Department of Cancer Systems Imaging Faculty Search Committee, 2020 - 2023
Member, DI - CABI Future Operations Sub-Committee, 2020 - 2023
Honors & Awards
| 2024 - 2026 | President, World Molecular Imaging Society |
| 2023 - 2024 | President Elect, World Molecular Imaging Society |
| 2023 | Outstanding Basic and/or Translational Research Award, The University of Texas MD Anderson Cancer Center |
| 2020 | UT Rising Star, The University of Texas System |
| 2020 | CPRIT Scholar in Cancer Research, Cancer Prevention and Research Institute of Texas |
| 2015 | Vanderbilt Trans-Institutional Program (TIPS) Award, Vanderbilt Center for Molecular Probes |
| 2015 | Distinguished Investigator Award, Academy of Radiology Research |
| 2015 | World Molecular Imaging Society Board of Trusts (elected) |
Professional Memberships
European Society of Molecular Imaging (ESMI)
2019 - Present
San Antonio Breast Cancer Symposium
2017 - Present
National Institutes of Health (NIH)
2016 - Present
National Cancer Institute (NCI)
2014 - Present
World Molecular Imaging Society (WMIS)
2013 - Present
Society of Radiopharmaceutical Sciences (SRS)
2013 - Present
National Cancer Institute (NCI)
2011 - Present
American Association for Cancer Research (AACR)
2009 - Present
American Association for the Advancement of Science (AAAS)
2009 - Present
Society of Nuclear Medicine and Molecular Imaging (SNMMI)
2007 - Present
American Chemical Society (ACS)
2004 - Present
Selected Presentations & Talks
Local Presentations
- 2025. New Radiopharmaceuticals for Cancer Imaging and Therapy. Invited. ERO/RO Seminar Series. Houston, TX, US.
- 2024. Radiotheranostics and Antibody Drug Conjugates. Invited. Oppenheimer Cancer Summit. Houston, Texas, US.
- 2024. The Suitability of 89Zr and 161Tb as a Theranostic Pair as Evaluated through Ex Vivo Biodistribution and Nuclear Imaging Studies in Mouse Models. Invited. 13th Annual Metabolism in Cancer Symposium. Houston, TX, US.
- 2024. Machine Learning Quantification of Pancreatic Remodeling and Tumor Progression from Histology in Genetically Engineered Mouse Model of Pancreatic Cancer. Invited. 13th Annual Metabolism in Cancer Symposium. Houston, Texas, US.
- 2023. Radiotheranostics and Antibody Drug Conjugates. Invited. Oppenheimer Cancer Summit. Houston, TX, US.
- 2023. Radiopharmaceuticals for Imaging, Prediction of Response, and Therapy. Invited. UTSW Radiation Oncology Summit. Houston, TX, US.
- 2023. Emerging Opportunities for Radionuclide Theranostics at MD Anderson. Invited. FY23 Brain Tumor Center Scientific Retreat. Houston, TX, US.
- 2022. Opportunities for Innovative Radiopharmaceutical Diagnostics and Therapeutics Discovery for GI Cancer. Invited. CCSG Gastrointestinal Program Research Retreat. Houston, TX, US.
Regional Presentations
- 2025. Evaluation of mucin 13 expression as a target for radioimmunotherapy: One step closer to a radionuclide theranostic strategy for colorectal cancer. Conference. 2025 International Conference on Cancer Health Disparities. Mission, TX, US.
- 2024. Glycloprotein-targeted radionuclide theranostic pair for CRC. Conference. SWRM 2024. Waco, TX, US.
- 2024. Identification and localization of low-grade premalignant pancreatic lesions at an early stage. Conference. UT Austin-MD Anderson Collaborative Research Summit. Austin, TX, US.
- 2024. The Suitability of 89Zr and 161Tb as a Theranostic Pair as Evaluated through Ex Vivo Biodistribution and Nuclear Imaging Studies in Mouse Models. Conference. UT Austin-MD Anderson Collaborative Research Summit. Austin, TX, US.
- 2024. A Pilot Clinical Trial of 18F-FSPG PET in Intrahepatic Cholangiocarcinoma Tumors. Conference. UT Austin-MD Anderson Collaborative Research Summit. Austin, TX, US.
- 2024. Preclinical evaluation of syndecan-1 targeted radionuclide theranostics approach in mouse models of pancreatic ductal adenocarcinoma. Conference. UT Austin-MD Anderson Collaborative Research Summit. Austin, TX, US.
- 2022. Feasibility of PET Imaging for Predicting Response to Combined Inhibition of EGFR and Glutaminolysis in KRAS WT CRC. Conference. Feasibility of PET Imaging for Predicting Response to Combined Inhibition of EGFR and Glutaminolysis in KRAS WT CRC. Galveston, TX, US.
- 2021. Radiopharmaceuticals at the interface of neuroscience and oncology?. Conference. UT Austin-MDACC. Austin, TX, US.
- 2021. Precision Imaging through Chemistry. Conference. Dallas, TX, US.
- 2021. PET Radiopharmaceuticals and Inhibitors of Cancer Metabolism. Conference. McAllen, TX, US.
- 2017. Precision Imaging Metrics for Quantitative Cancer Medicine. Conference. Nashville, TN, US.
- 2014. Risk Stratification of Pancreatic Adenocarcinoma Precursor Lesions using TSPO-PET. Conference. Nashville, TN, US.
- 2012. Advanced imaging of the GI Track. Conference. Nashville, TN, US.
- 2011. Role of Imaging in Drug Discovery and Cancer Research. Conference. Nashville, TN, US.
National Presentations
- 2025. CGMP-compliant automated [18F]DASA-10 production for clinical monitoring of pyruvate kinase M2. Poster. Society of Nuclear Medicine & Molecular Imaging Annual Meeting. New Orleans, LA, US.
- 2025. PET Radiopharmacy users’ forum. Panelist. Society of Nuclear Medicine & Molecular Imaging. New Orleans, LA, US.
- 2025. Theranostics Stakeholders Summit. Panelist. Reston, VA, US.
- 2025. Preclinical Fluorescence-1 Guided Localization of High-Risk Premalignant Pancreatic Lesions Leveraging Surrounding Sentinel Tumor Microenvironment. Poster. 2025 Preclinical Imaging Consortium. Houston, TX, US.
- 2024. New Radiopharmaceuticals for Cancer Imaging and Therapy. Invited. Detroit, MI, US.
- 2024. Technology Enabling Radionuclide Theranostics. Invited. Southwest Regional American Chemical Society,. Waco, TX, US.
- 2024. MD Anderson RADIATE: a model for academic theranostics discovery at industry scale. Invited. Jackson Hole, WY, US.
- 2024. "Molecular Imaging". Invited. The 3rd Britton Chance International Symposium on Metabolic Imaging/Spectroscopy. Philadelphia, PA, US.
- 2024. TSPO-targeted near-infrared optical probe for early identification and localization of high-risk premalignant pancreatic lesions. Poster. AACR Annual Meeting 2024. San Diego, CA, US.
- 2024. Access to Radiopharmaceuticals for Imaging and Therapy: the need, current challenges, and prospects for a bright future.”. Conference. Access to Radiopharmaceuticals for Imaging and Therapy: the need, current challenges, and prospects for a bright future.”. Mission, TX, US.
- 2024. Assessment of Mucin 13 (MUC13) as an Imaging Target for Guiding Colorectal Cancer Treatment: A Pathway Towards Theranostic Development. Poster. 2nd International Conference on Cancer Health Disparities at the UTRGV School of Medicine Research Symposium. Mission, TX, US.
- 2023. Developing a Novel Microfluidics-based 86Y purification strategy for Rapid and Efficient Radiopharmaceutical production. Poster. 25th ISRS. Honolulu, HI, US.
- 2023. Evaluating the radionuclide theranostic potential of a MUC13-targeting antibody in colorectal cancer. Poster. 25th ISRS. Honolulu, HI, US.
- 2022. Targeting Cancer Metabolism for Molecular Imaging and Therapy. Invited. St. Louis, MO, US.
- 2021. High-yielding radiosyntheses of PET imaging radiopharmaceuticals using a low-cost microfluidic device. Invited. The International Chemical Congress of Pacific Basin Societies (ICCPBS) Virtual Meeting. Honolulu, HI, US.
- 2021. Radiopharmaceuticals for Precision Cancer Imaging and Therapy. Conference. Joint Department of Energy (DOE). Virtual Meeting, US.
- 2019. First-in-human PET imaging study using [68Ga]-Folate tracer, [68Ga]EC2115. Poster. Society of Nuclear Medicine & Molecular Imaging Annual Meeting. Anaheim, CA, US.
- 2018. Modification of a Commercial Radiochemistry Module for Facile Production of [11C]Palmitate. Poster. World Molecular Imaging Society Annual Meeting. Seattle, WA, US.
- 2018. Exploratory Labeling of Potent ASCT2 Inhibitors for Use as Imaging Biomarkers. Poster. World Molecular Imaging Society Annual Meeting. Seattle, WA, US.
- 2018. Development of a Microfluidic System for [18F]Radiopharmaceutical Synthesis. Conference. Development of a Microfluidic System for [18F]Radiopharmaceutical Synthesis. Seattle, WA, US.
- 2018. Development of PET Imaging Biomarkers to Predict Response to Inhibition of Glutamine Metabolism in Colorectal Cancer. Poster. World Molecular Imaging Society Annual Meeting. Seattle, WA, US.
- 2018. Targeting Glutamine Metabolism to Enhance Photodynamic Therapy. Poster. World Molecular Imaging Society Annual Meeting. Seattle, WA, US.
- 2018. The Automated and Manual Production Comparison of [68Ga}-EC2115. Poster. World Molecular Imaging Society Annual Meeting. Seattle, WA, US.
- 2018. Optimization of the Production of [18F]FPEB for Preclinical Use. Poster. World Molecular Imaging Society Annual Meeting. Seattle, WA, US.
- 2018. New Tracers of Glutamine Metabolism. Invited. Third AACR-SNMMI Joint Conference on State-of-the-Art Molecular Imaging in Cancer Biology and Therapy. San Diego, CA, US.
- 2017. Production of [99mTc]-Fibrinogen for Visualization of Gastrointestinal Bleeds. Poster. World Molecular Imaging Congress Annual Meeting. Philadelphia, PA, US.
- 2017. Novel Theranostics Targeting Glutamine Metabolism in Solid Tumors. Poster. World Molecular Imaging Congress Annual Meeting. Philadelphia, PA, US.
- 2017. Developments Towards Realtime Radioactivity Monitoring on a Standalone Microfluidic Chip. Poster. World Molecular Imaging Congress Annual Meeting. Philadelphia, PA, US.
- 2017. Development of a Modified Production of [18F]FET for Preclinical Use. Poster. World Molecular Imaging Congress Annual Meeting. Philadelphia, PA, US.
- 2017. Preclinical Evaluation of a Novel TSPO-PET Ligand 2-(7-Butyl-2-(4-(2-[18F]Fluoroethoxy)phenyl)-5-Methylpyrazolo[1,5-a]Pyrimidin-3-yl)-N,N-Diethylacetamide (18F-VUIIS1018A) to Image Glioma. Poster. World Molecular Imaging Congress Annual Meeting. Philadelphia, PA, US.
- 2017. Modification of a Commercial Radiochemistry Module for facile cGMP Production of [11C]L-Glutamine. Poster. World Molecular Imaging Congress Annual Meeting. Philadelphia, PA, US.
- 2017. Structural modeling and ligand discovery of ASCT2 utilizing in silico methodology. Poster. World Molecular Imaging Congress Annual Meeting. Philadelphia, PA, US.
- 2017. Automated Clinical Product of [11C]Glutamine on Commercial Synthesis Modules. Poster. (SNMMI) Society of Nuclear Medicine and Molecular Imaging Annual Meeting. Denver, CO, US.
- 2017. A Novel Molecular Imaging Probe for Optical Surgical Navigation of Pancreatic Cancer. Poster. (SNMMI) Society of Nuclear Medicine and Molecular Imaging Annual Meeting. Denver, CO, US.
- 2017. Targeting Glutamine Metabolism to Enhance EGFR Blockade. Invited. National Gastrointestinal SPORE Meeting. Nashville, TN, US.
- 2017. New PET Tracers to Improve Radiation Planning. Invited. SWOG Radiation Oncology Annual Meeting. San Francisco, CA, US.
- 2017. A Simple Microfluidic Device for Multistep Synthesis of Radioactive Fallypride. Poster. MicroTAS International Conference. Savannah, GA, US.
- 2016. Investigation of Gallium-68 Labeled RM2 in a Mouse Model of PSA/PSMA Negative Prostate Cancer. Poster. World Molecular Imaging Congress Annual Meeting. New York, NY, US.
- 2016. Radiolabeling of CD8 Antigen, A Systematic Comparison of SPECT vs. PET. Poster. World Molecular Imaging Congress Annual Meeting. New York, NY, US.
- 2016. Glutamine Metabolism as a Target in Colorectal Cancer and Evaluation of Therapeutic Response. Poster. World Molecular Imaging Congress Annual Meeting. New York, NY, US.
- 2016. Phase I Clinical Trial of 18F-FSPG PET Imaging to Diagnose and Stage Hepatocellular Carcinoma (HCC): Comparison with SOC MRI 11C-Acetate, and Beyond. Poster. World Molecular Imaging Congress Annual Meeting. New York, NY, US.
- 2016. New Structure-activity Relationships of N- acetamide Substituted Pyrazolopyrimidines as Pharmacological Ligands of TSPO. Poster. World Molecular Imaging Congress Annual Meeting. New York, NY, US.
- 2016. A Novel Molecular Imaging Probe for Optical Surgical Navigation of Pancreatic Cancer. Poster. World Molecular Imaging Congress Annual Meeting. New York, NY, US.
- 2016. Harnessing Inflammation, Cancer and the Convergence, Immuno-oncology. Poster. Society of Nuclear Medicine and Molecular Imaging Annual Meeting. San Diego, CA, US.
- 2016. Clinical Evaluation of 18F-FSPG PET in Hepatocellular Carcinoma (HCC) Compared with 11C-Acetate. Poster. Society of Nuclear Medicine and Molecular Imaging Annual Meeting. San Diego, CA, US.
- 2016. Glutamine PET to Predict Response to Dual Pharmacological Inhibition of BRAFV600E and PI3K/mTOR Pathway Activity in vivo. Poster. Society of Nuclear Medicine and Molecular Imaging Annual Meeting. San Diego, CA, US.
- 2016. Design and Evaluation of Chemical Probes Targeting ASCT2 (SLC1A5) as Precision Cancer Imaging Diagnostics. Poster. Society of Nuclear Medicine and Molecular Imaging Annual Meeting. San Diego, CA, US.
- 2016. Exploring the Radiofluorination Efficiency of Electron Rich Aromatic Rings. Poster. World Molecular Imaging Congress Annual Meeting. New York, NY, US.
- 2016. “On-chip [18F]fluoride concentration for microfluidic PET tracer synthesis. Poster. Nashville, TN, US.
- 2015. New Insights into the Radiosynthesis of the DAT Imaging PET Tracer [18F]FE-PE2I. Poster. World Molecular Imaging Congress Annual Meeting. Honolulu, HI, US.
- 2015. Towards the Design of Novel Molecular Imaging Probes Targeting ASCT2. Poster. World Molecular Imaging Congress Annual Meeting. Honolulu, HI, US.
- 2015. An Optimized Fluorescent TSPO Ligand for in Vitro Screening and Imaging. Poster. World Molecular Imaging Congress Annual Meeting. Honolulu, HI, US.
- 2014. Molecular imaging of glutaminolysis as a tool for evaluating therapeutic response in preclinical models of colorectal cancer. Poster. American Association for Cancer Research Annual Meeting. San Diego, CA, US.
- 2014. Preclinical evaluation of 7-chloro-N,N,5-trimethyl-4-oxo-3(6-[18F]fluoropyridin-2-yl)-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide: A novel pyridazinoindole ligand for PET imaging of TSPO in cancer. Poster. (SNMMI) Society of Nuclear Medicine and Molecular Imaging Annual Meeting. St. Louis, MO, US.
- 2014. TSPO in inflammation and cancer. Invited. Society of Nuclear Medicine and Molecular Imaging Annual Meeting Education program. St. Louis, MO, US.
- 2014. Preclinical evaluation of 7-chloro-N,N,5-trimethyl-4-oxo-3(6-[18F]fluoropyridin-2-yl)-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide: A novel pyridazinoindole ligand for PET imaging of TSPO in cancer. Poster. (AACR) American Association of Cancer Research Annual Meeting. San Diego, CA, US.
- 2014. PET tracers to quantify genetic events. Invited. NCI GI and Pancreas SPORE Workshop, US.
- 2013. [18F]-FLT PET to predict early response to neoadjuvant therapy in rectal cancer. Poster. Chicago, IL, US.
- 2013. Translocator Protein (TSPO): Potential as a novel biomarker in renal cell carcinoma. Poster. San Diego, CA, US.
- 2013. Imaging Modalities to Assay Molecular Biomarkers of Resistance in Pancreatic Cancer. Poster. Miami, FL, US.
- 2012. Positron emission tomography (PET) of TSPO expression in preclinical models of human cancer. Poster. American Association for Cancer Research Annual Meeting 2012. Chicago, IL, US.
- 2012. Limits of [18F]-FLT PET as a predictive imaging biomarker of proliferation in oncology. Poster. American Association for Cancer Research Annual Meeting 2012. Chicago, IL, US.
- 2012. Prognostic implications of TSPO in human colorectal cancer. Poster. American Association for Cancer Research Annual Meeting 2012. Chicago, IL, US.
- 2012. Translocator protein (TSPO) as an imaging target in pancreatic cancer. Poster. AACR-SNMMI Joint Conference on State-of-the-Art Molecular Imaging in Cancer Biology and Therapy. San Diego, CA, US.
- 2012. Positron emission tomography (PET) imaging analogs of glutamic Development and evaluation as probes for cancer imaging. Poster. American Association for Cancer Research Annual Meeting 2012. Chicago, IL, US.
- 2011. Imaging to Characterize and Validate Preclinical Cancer Models. Invited. Washington, DC, US.
- 2011. TSPO PET ligands [18F]PBR06 and [18F]DPA-714 for glioma imaging: a preclinical comparison of kinetic parameters. Poster. Society of Nuclear Medicine Annual Meeting 2011. San Antonio, TX, US.
- 2011. [18F]-FLT PET imaging to assess therapeutic response to EGFR blockade in Ménétrier’s disease. Poster. Society of Nuclear Medicine Annual Meeting 2011. San Antonio, TX, US.
- 2011. Microfluidic production of 18F-labeled TSPO ligands. Poster. Society of Nuclear Medicine Annual Meeting 2011. San Antonio, TX, US.
- 2011. Preclinical evaluation of TSPO ligand [18F]DPA-714 for PET imaging of glioma. Poster. Society of Nuclear Medicine Annual Meeting 2011. San Antonio, TX, US.
- 2011. PET imaging of infiltrative, primary human glioma xenografts using TSPO ligand [18F]PBR06. Poster. Society of Nuclear Medicine Annual Meeting 2011. San Antonio, TX, US.
- 2011. Correlating 18FLT Uptake with B-RAF Inhibition Using MALDI-IMS. Poster. Society of Nuclear Medicine Annual Meeting 2011. San Antonio, TX, US.
- 2011. Molecular probes for cancer imaging and assessment of treatment response. Invited. 102nd Annual Meeting of the AACR. Orlando, FL, US.
- 2011. Future Directions in the Molecular imaging of Breast Cancer. Invited. SNM’s Center for Molecular Imaging Innovation & Translation’s Breast Cancer Imaging and Treatment: State of the Art. Bethesda, MD, US.
- 2010. Thymidine salvage to reflect tumor cell proliferation: implications for 18FLT PET as a biomarker in oncology. Poster. Society of Nuclear Medicine (SNM) Annual Meeting. Salt Lake City, UT, US.
- 2010. [18F]FDG-PET as a rapid, non-invasive pharmacodynamic marker of response to IGF1-R/IR targeted therapy in preclinical models. Poster. Society of Nuclear Medicine (SNM) Annual Meeting. Salt Lake City, UT, US.
- 2010. TSPO ligands for PET imaging of cancer. Poster. Society of Nuclear Medicine (SNM) Annual Meeting. Salt Lake City, UT, US.
- 2010. Parlaying a K-award into an RO1. Invited. American Association of Cancer Research Annual Meeting. Washington, DC, US.
- 2010. Non-Invasive, Real-Time Assessment of Early PharmacodynaEffects for the IGF1-R/IR Inhibitor OSI-906 by [18F]-FDG-PET. Poster. Washington, DC, US.
- 2009. Resistance to Endocrine Therapy in Estrogen Receptor-Positive (ER+) Breast Cancer Is Dependent upon Phosphatidylinositol-3 Kinase (PI3K) Signaling. Poster. San Antonio, TX, US.
- 2009. A combinatorial approach for analyzing the MALDI response of small molecules. Poster. Philadelphia, PA, US.
- 2008. Molecular imaging to profile response to EGF receptor axis blockade in mice and man. Poster. First National Cancer Institute (NCI) Translates Translational Science Meeting. Washington, DC, US.
- 2008. Molecular Imaging Research and Development. Invited. Missouri Valley Chapter of the Society of Nuclear Medicine (SNM). Omaha, NE, US.
- 2008. Molecular imaging to profile response to EGF receptor axis blockade in mice and man. Poster. Huntington Beach, CA, US.
- 2008. Molecular imaging to profile response to EGF receptor axis blockade in mice and man. Poster. Semi-Annual NCI Mouse Models of Human Cancer Consortium (MMHCC) Steering Committee Meeting. Bethesda, MD, US.
- 2007. Molecular imaging biomarkers of response to EGF-axis blockade in colorectal cancer. Poster. Advances in Colon Cancer Research. Cambridge, MA, US.
- 2007. Molecular imaging assessment of tumor angiogenesis and treatment response in pre-clinical models of human cancer. Poster. Providence, RI, US.
- 2007. Non-invasive imaging metrics to profile treatment response in models of CRC. Poster. Fifteenth Annual NCI SPORE Investigators Meeting. Baltimore, MD, US.
- 2007. A Role for High-throughput Screening in Imaging Agent Development?. Poster. Nashville, TN, US.
- 2006. A High-Throughput Molecular Imaging Screen to Monitor Therapeutic Response In Vivo. Poster. Cambridge Health Institute: Third Annual "In Vivo Molecular Imaging". La Jolla, CA, US.
- 2006. A High-Throughput Molecular Imaging Screen to Monitor Therapeutic Response In Vivo. Poster. Molecular Diagnostics in Cancer Therapeutic Development. Chicago, IL, US.
- 2005. Disease Progression and Therapeutic Efficacy Monitoring in EAE using a NIR PBR Targeted Molecular Imaging Agent. Poster. Jackson Hole, WY, US.
- 2003. Lanthanide Chelates as Multi-Use Molecular Imaging Agents. Poster. San Jose, CA, US.
- 2002. Synthesis and Physical Spectroscopy of Lanthanide Chelates as Contrast Agents. Poster. San Jose, CA, US.
- 2001. Lanthanide Chelate Spectroscopy: Correlating 7FJ¬5D0 Emission Spectra with Structure. Poster. Southwestern American Chemical Society Regional Meeting. San Antonio, TX, US.
International Presentations
- 2025. Preclinical evaluation of mucin-13 targeted radionuclide theranostics approach suitable for metastatic colorectal cancer. Poster. 26th International Symposium on Radiopharmaceutical Sciences. Gold Coast in Queensland, AU.
- 2025. 177Lu-labeled antibody-drug conjugate: a dual mechanistic treatment modality in solid tumors with heterogeneous antigen expression. Poster. 26th International Symposium on Radiopharmaceutical Sciences. Gold Coast in Queensland, AU.
- 2024. New Theranostic Radiopharmaceutical Development at MD Anderson Cancer Center. Invited. 17th Hangzhou International Molecular Imaging Conference. Hangzhou, CN.
- 2024. Preclinical evaluation of syndecan-1 targeted radionuclide theranostic approach in mouse models of pancreatic cancer. Poster. World Molecular Imaging Congress 2024. Montreal, CA.
- 2024. Factors impacting radioisotope supply chain management in an academic theranostics program: the MD Anderson experience. Poster. World Molecular Imaging Congress 2024. Montreal, CA.
- 2024. The challenges and benefits to developing a Laboratory Manual as a management tool in a theranostics R&D laboratory. Poster. World Molecular Imaging Congress 2024. Montreal, CA.
- 2024. The Suitability of 89Zr and 161Tb as a Theranostic Pair as Evaluated through Ex Vivo Biodistribution and Nuclear Imaging Studies in Mouse Models. Poster. World Molecular Imaging Congress 2024. Montreal, CA.
- 2024. Novel B cell gene signature associated with response to glutaminolytic-EGFR axis in colorectal cancer. Poster. World Molecular Imaging Congress 2024. Montreal, CA.
- 2024. Annotating the Metabolic Landscape of Pancreatic Cancer with Pharmacological Blockade of ASCT2. Poster. World Molecular Imaging Congress 2024. Montreal, CA.
- 2024. Learning Quantification of Pancreatic Remodeling and Tumor Progression from Histology in Genetically Engineered Mouse Model of Pancreatic Cancer. Poster. World Molecular Imaging Congress 2024. Montreal, CA.
- 2024. Combination Therapy of ASCT2 Inhibitor V-9302 and PD-1 Blockade Inhibits Tumor Growth and Improves Anti-tumor Immunity in Melanoma Mouse Models. Poster. World Molecular Imaging Congress 2024. Montreal, CA.
- 2024. Simple universal strategy to prepare 18F-labeled amino acid analogues. Poster. Society of Nuclear Medicine and Molecular Imaging Annual Meeting. Toronto, CA.
- 2024. Novel B Cell Gene Signature Linked to Response to Combined EGFR and Glutaminolysis Blockade in KRAS Wild-Type Metastatic Colorectal Cancer. Poster. The Eighth JCA-AACR Special Joint Conference. Kyoto, JP.
- 2024. Potential of MUC13 as a target for radionuclide theranostics approach suitable for metastatic colorectal cancer. Poster. The 18th Annual Meeting of Japanese Society for Molecular Imaging. Tokyo, JP.
- 2024. MD Anderson RADIATE – An end-to-end research platform to drive radiopharmaceutical therapeutics discovery. Poster. The 18th Annual Meeting of Japanese Society for Molecular Imaging. Tokyo, JP.
- 2024. Mucin 13 (MUC13) as an imaging target for radioimmuno-PET: Towards development of a theranostic strategy for colorectal cancer treatment. Poster. 7th Theranostics World Conference. Santiago, CL.
- 2023. Radiopharmaceuticals for Imaging and Therapy. Hangzhou, CN.
- 2023. Optimizing Routine Production of [C-11]HCN for PET Tracer Development and Clinical Trials. Poster. World Molecular Imaging Congress 2023 (WMIC). Prague, CZ.
- 2023. Targeted Near-infrared Optical Imaging of Cholesterol Metabolism to Facilitate Surgery of Pancreatic Cancer. Poster. World Molecular Imaging Congress 2023 (WMIC). Prague, CZ.
- 2023. A novel “Gene plus PET imaging” signature predicts clinical response to combined EGFR and glutaminolysis inhibition in KRAS wild-type colorectal cancer. Poster. World Molecular Imaging Congress 2023 (WMIC). Prague, CZ.
- 2023. Potential of MUC13 as a target for radionuclide theranostics—Comprehensive molecular profiling in well-annotated human colon cancer specimens. Poster. World Molecular Imaging Congress 2023 (WMIC). Prague, CZ.
- 2023. ASCT2 Inhibitor V-9302 and PD-1 Blockade Inhibits Glutamine Metabolism and Reduces Tumor Growth in Melanima Mouse Models. Poster. World Molecular Imaging Congress 2023 (WMIC). Prague, CZ.
- 2023. A Pilot Clinical Trial of 18F-FSPG PET in Intrahepatic Cholangiocarcinoma Tumors. Poster. World Molecular Imaging Congress 2023 (WMIC). Prague, CZ.
- 2023. Simplified 18F-FSPG production by FASTlabTM synthesizer at reliably high yield for clinical investigations. Poster. World Molecular Imaging Congress 2023 (WMIC). Prague, CZ.
- 2023. An 18F-radioligand targeting the glutamine transporter ASCT2. Poster. World Molecular Imaging Congress 2023 (WMIC). Prague, CZ.
- 2023. Preclinical 18F-FSPG PET of hepatocellular carcinoma in MUP-uPA transgenic mouse model. Poster. World Molecular Imaging Congress 2023 (WMIC). Prague, CZ.
- 2023. 18F-FSPG PET-derived signature for early response assessment to combined blockade of EGFR and glutamine metabolism in wild-type KRAS colorectal cancer. Poster. 18th European Molecular Imaging Meeting | EMIM 2023. Salzburg, AT.
- 2023. 18F-FSPG PET Imaging of Intrahepatic Cholangiocarcinoma Tumors, a Pilot Clinical Trial. Poster. 18th European Molecular Imaging Meeting | EMIM 2023. Salzburg, AT.
- 2022. Targeting glutamine metabolism for drug development and theranostics. Invited. 13th Congress of the WFNMB - World Federation of Nuclear Medicine and Biology 2022. Kyoto, JP.
- 2020. TSPO as an Actionable Imaging Biomarker: Development of Targeted Molecular Imaging Agents for Positron Emission Tomography (PET) and Optical Surgical Navigation of Pancreatic Cancer. Poster. European Molecular Imaging Meeting. Thessaloniki, GR.
- 2020. Development of PET Imaging Biomarkers of Glutamine Metabolism-Targeted Treatments Through Clinical Imaging Trial. Poster. European Molecular Imaging Meeting. Thessaloniki, GR.
- 2019. First-in-human PET imaging study using [68Ga]-Folate tracer, [68Ga]EC2115: Evaluation of Safety and Dosimetry. Poster. World Molecular Imaging Society Annual Meeting. Montreal, CA.
- 2019. PET Imaging to Elucidate the Mechanism of Action of Glutamine Transport Inhibition in Pancreatic Cancer. Poster. World Molecular Imaging Society Annual Meeting. Montreal, CA.
- 2019. A Novel TSPO-Targeted Molecular Imaging Agent for Optical Surgical Navigation of Pancreatic Cancer. Poster. World Molecular Imaging Society Annual Meeting. Montreal, CA.
- 2019. Development of PET Imaging Biomarkers of Glutamine Metabolism-Targeted Treatments Through Co-Clinical Imaging Trials. Poster. World Molecular Imaging Society Annual Meeting. Montreal, CA.
- 2017. Molecular Imaging of Cancer Metabolism. Invited. Sydney, AU.
- 2017. Vanderbilt Center for Molecular Probes and Molecular Imaging Research. Invited. Lisbon, PT.
- 2017. New PET Tracers of Cancer Metabolism. Invited. Amsterdam, NL.
- 2016. Development of a Glutamine Transport Inhibitor: A Novel Therapeutic Strategy in Oncology. Poster. Keystone Symposia on Tumor Metabolism: Mechanisms and Targets. Whistler, CA.
- 2014. Preclinical Evaluation of 7-Chloro-N,N,5-trimethyl-4-oxo-3(6- [18F]fluoropyridin-2-yl)-3,5-dihydro-4H-pyridazino[4,5-b]indole-1- acetamide: A Novel Pyridazinoindole Ligand for PET Imaging of TSPO in Cancer. Poster. World Molecular Imaging Congress. Seoul, KR.
- 2014. Towards the Design of Novel Molecular Imaging Probes Targeting ASCT2 for Cancer Imaging. Poster. World Molecular Imaging Congress. Seoul, KR.
- 2014. PET tracers for molecular imaging in oncology. Invited. Uppsala, SE.
- 2014. Advances Towards the Optimization of 18F-Fluorodihydrotestosterone for Use in Pre-Clinical Prostate Imaging. Poster. World Molecular Imaging Congress Annual Meeting. Seoul, KR.
- 2013. Translocator protein (TSPO) as a molecular imaging biomarker of pancreatic cancer. Poster. Vancouver, CA.
- 2011. Microfluidic production of 18F-labeled TSPO Ligands. Poster. 19th Annual International Symposium of Radiopharmaceutical Sciences (ISRS). Amsterdam, NL.
- 2009. Molecular imaging of therapeutic response to EGF receptor blockade in colorectal cancer. Poster. Society of Nuclear Medicine (SNM) Annual Meeting. Toronto, CA.
- 2008. Quantitative assessment of multimodal imaging metrics for monitoring treatment response in mouse models of colorectal carcinoma. Poster. World Molecular Imaging Congress. Nice, FR.
- 2008. Prediction of treatment response to HER2-directed therapy of breast cancer using multimodal molecular imaging. Poster. World Molecular Imaging Congress. Nice, FR.
- 2008. A molecular imaging paradigm to rapidly profile response to angiogenesis-directed therapy in small animals. Poster. World Molecular Imaging Congress. Nice, FR.
Formal Peers
- 2024. 3rd Britton Chance International Symposium on Metabolic Imaging/Spectroscopy. Invited. Philadelphia, PA, US.
- 2022. Probing metabolism in the tumor microenvironment using radiopharmaceuticals. Invited. St. Louis, MO, US.
- 2020. Opportunities and Directions in Cancer Metabolism Research Enabled by Quantitative Imaging. Invited. San Francisco, CA, US.
- 2017. Precision Imaging Metrics for Quantitative Cancer Medicine. Invited. Nashville, TN, US.
- 2014. PET tracers to quantify genetic events. Invited, US.
- 2014. PET tracers for molecular imaging in oncology. Invited, SE.
- 2014. Risk Stratification of Pancreatic Adenocarcinoma Precursor Lesions using TSPO-PET. Invited. Nashville, TN, US.
- 2013. Imaging Modalities to Assay Molecular Biomarkers of Resistance in Pancreatic Cancer. Invited. Miami, FL, US.
- 2012. Advanced imaging of the GI Track. Invited. Nashville, TN, US.
- 2011. Molecular Probes for Cancer Imaging and Research. Invited. Dallas, TX, US.
- 2011. Preclinical Imaging Tools for Cancer Research. Invited. Lincoln, NE, US.
- 2011. Role of Imaging in Drug Discovery and Cancer Research. Invited. Nashville, TN, US.
- 2011. TSPO Ligands for Imaging Glioma. Invited. Nashville, TN, US.
- 2011. Molecular Probes for Cancer Imaging. Invited. Dallas, TX, US.
- 2011. Imaging to Characterize and Validate Preclinical Cancer Models. Invited. Washington, DC, US.
- 2011. Correlating In Vivo Imaging with Histology. Invited. Davis, CA, US.
- 2011. Cancer Imaging Biomarkers of Treatment Response. Invited. Indianapolis, IN, US.
- 2010. Molecular Probes for Cancer Imaging: Discovery and Validation. Invited. New York, NY, US.
- 2010. Molecular Probes for Cancer Imaging: Discovery and Validation. Invited. Baltimore, MD, US.
- 2010. Molecular Probes for Cancer Imaging: Discovery and Validation. Invited, US.
- 2010. Correlating imaging with histology. Invited. Davis, CA, US.
Grant & Contract Support
| Date: | 2026 - 2028 |
| Title: | " Spanning the d-block: bimetallic macrocyclic chelators to carry disparate theranostic radiometals" |
| Funding Source: | NIH |
| Role: | PI |
| Date: | 2026 - 2031 |
| Title: | Cell Surface Mucin 13-targeted Radionuclide Theranostics for Colorectal Cancer |
| Funding Source: | NIH |
| Role: | PI |
| Date: | 2025 - 2030 |
| Title: | Drug-loaded degradable biopolymeric scaffolds for augmenting preoperative liver growth |
| Funding Source: | NIH |
| Role: | Co-I |
| Date: | 2025 - 2028 |
| Title: | MUC13 Targeted Theranostics for Colorectal Cancer |
| Funding Source: | CPRIT |
| Role: | PI |
| Date: | 2025 - 2028 |
| Title: | Combining FLASH-RT with oxygen-modifying drugs to treat pancreatic cancer |
| Funding Source: | NIH |
| Role: | Collaborator |
| ID: | 1F30CA301794-01A1 |
| Date: | 2025 - 2030 |
| Title: | Rationale targeting of the cell cycle to sensitize soft tissue sarcomas to chemotherapy through a biomarker-based approach |
| Funding Source: | NIH |
| Role: | PI |
| Date: | 2025 - 2025 |
| Title: | The function of IgA positive B cells in gastrointestinal cancers |
| Funding Source: | NIH |
| Role: | Key |
| ID: | 1R01CA304326-01 |
| Date: | 2025 - 2027 |
| Title: | IL13Ra2-targeted radioimmunotherapy for glioblastoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2025 - 2030 |
| Title: | Single-use Microfluidic Device for Radiopharmaceutical Production |
| Funding Source: | NIH |
| Role: | Co-PI |
| ID: | R01EB034665 |
| Date: | 2025 - 2029 |
| Title: | Theranostic Targeting Cancer Specific Glycoprotein Expression |
| Funding Source: | NIH |
| Role: | PI |
| ID: | R01CA292517 |
| Date: | 2025 - 2030 |
| Title: | Mesenchymal stem cell-loaded biopolymeric scaffolds for augmenting the preoperative liver growth |
| Funding Source: | NIH |
| Role: | Co-I |
| Date: | 2025 - 2029 |
| Title: | Metal Intervention Network and Therapy (MINT) Program: Studying and targeting metal response in tumor radioresistance |
| Funding Source: | University of Texas at Austin/The University of Texas MD Anderson Cancer Center |
| Role: | Co-I |
| ID: | N/A |
| Date: | 2025 - 2026 |
| Title: | Interrogating the in vivo pharmacokinetics of armored CARs with radiohapten capture |
| Funding Source: | National Institutes of Health/National Cancer Institute |
| Role: | Co-I |
| ID: | 7R37CA262557-05 |
| Date: | 2024 - 2028 |
| Title: | CPRIT-MIRA Proposed components Project 2. Molecular-PET (m-PET) Imaging Probes for Pancreatic Cancer |
| Funding Source: | CPRIT |
| Role: | Co-I |
| Date: | 2024 - 2029 |
| Title: | Novel PET Imaging to Guide Therapy in Hepatocellular Carcinoma |
| Funding Source: | NIH |
| Role: | PI |
| ID: | R01CA279467 |
| Date: | 2024 - 2026 |
| Title: | Lactic acid bacteria as the ultimate Trojan Horse for targeted radionuclide delivery |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| Date: | 2024 - 2027 |
| Title: | Development of Radiopaque and Drug-Eluting Absorbable Vascular Grafts |
| Funding Source: | American Heart Association |
| Role: | Consult |
| Date: | 2024 - 2025 |
| Title: | Radionuclide Theranostic for BRAF-mutated CRC |
| Funding Source: | Colorectal Cancer Alliance |
| Role: | PI |
| Date: | 2024 - 2027 |
| Title: | Translational theranostic pair against CAIX |
| Funding Source: | C BioMex |
| Role: | PI |
| Date: | 2024 - 2025 |
| Title: | NanoScan SPECT 4H / CT1512 / PET122S in-vivo imager |
| Funding Source: | NIH/NCI |
| Role: | Major User |
| ID: | 1S10OD036241-01 |
| Date: | 2023 - 2030 |
| Title: | Nanoparticle-Enhanced Absorbable Medical Devices for Management of Vascular Diseases |
| Funding Source: | NIH/NHLBI |
| Role: | Co-I |
| ID: | PENDING |
| Date: | 2023 - 2028 |
| Title: | The MD Anderson/Johns Hopkins Cholangiocarcinoma ROBIN Center: Molecular Characterization Trial |
| Funding Source: | NIH/NCI |
| Role: | Co-Program Leader |
| ID: | U54CA274281 |
| Date: | 2023 - 2028 |
| Title: | Cancer Systems Biology Center of Glioblastoma Management |
| Funding Source: | Texas A&M University |
| Role: | Co-I |
| ID: | FP00017945 |
| Date: | 2023 - 2028 |
| Title: | Quantitative and Integrated Immunologic And Diffusion Weighted Imaging For Predicting Response To Neoadjuvant Chemoradiation In Esophageal Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | PENDING |
| Date: | 2023 - 2028 |
| Title: | Low-cost, Single-use Microfluidic Device for Radiopharmaceutical Production |
| Funding Source: | NIH/NIBIB |
| Role: | PI |
| ID: | 1 RO1 EB034665-01 |
| Date: | 2023 - 2026 |
| Title: | Integrated Microfluidic Purification and Complexation of Cyclotron-produced Metals for Radiopharmaceutical Production |
| Funding Source: | Welch Foundation |
| Role: | PI |
| ID: | N/A |
| Date: | 2023 - 2024 |
| Title: | Innovative PET to Prioritize Oligometastases for Radiation Therapy |
| Funding Source: | The University of Texas MD Anderson Cancer Center QIAC Partnership in Research |
| Role: | Co-PI |
| Date: | 2023 - 2025 |
| Title: | Quantitative Imaging of OXPHOS in Pancreatic Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R21CA280238 |
| Date: | 2023 - 2028 |
| Title: | Novel Radiolabeled Probes for Ovarian Cancer Imaging and Treatment |
| Funding Source: | UTRGV/NIH/NCI |
| Role: | Principal Investigator-MDACC |
| ID: | R01CA268732-01A1 |
| Date: | 2023 - 2028 |
| Title: | Novel PET Imaging to Guide Therapy in Hepatocellular Carcinoma |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01CA279467 |
| Date: | 2023 - 2026 |
| Title: | Disruptive Low-Cost Microfluidic Technology to Deliver Radiopharmaceuticals for Cancer Diagnosis and Therapy |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP230177 |
| Date: | 2023 - 2026 |
| Title: | PET Imaging of Immunotherapy-Induced Adverse Events |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP230238 |
| Date: | 2023 - 2030 |
| Title: | A Phase 1 Study to Access the Pharmacokinetics of [18F] GEH121224 and Determine the Optimal Timing of Imaging in Patients with Locally Advanced or Metastatic Breast Cancer |
| Funding Source: | GE Healthcare |
| Role: | PI |
| ID: | GE-226-004 |
| Date: | 2022 - 2024 |
| Title: | First-in-Human Imaging of Innate Immunity Activation with a Redox-Tuned PET Reporter |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1-R21 CA277283-01 |
| Date: | 2022 - 2027 |
| Title: | RAPID: A Low-Cost Device for Radiopharmaceutical Production |
| Funding Source: | NIH/NIBIB |
| Role: | PI |
| ID: | R01EB033793 |
| Date: | 2022 - 2027 |
| Title: | [18F]4FN PET Imaging of Innate Immunity Activation During Immunotherapy-Induced Adverse Events |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA273130 |
| Date: | 2022 - 2025 |
| Title: | Disrupting Access to Intracellular Lipid Depots to Treat Advanced Prostate Cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| ID: | PC210481 |
| Date: | 2022 - 2023 |
| Title: | Glutamine PET Imaging of Head and Neck Cancers |
| Funding Source: | The University of Texas MD Anderson Cancer Center - Institutional Research Grant |
| Role: | PI |
| Date: | 2022 - 2025 |
| Title: | Highly Specific and Potent Inhibitors of the Glutamine Transporter ASCT2 as a Therapy for Colorectal Cancer |
| Funding Source: | AxImmune, Inc / National Institutes of Health |
| Role: | Co-I |
| ID: | TBD |
| Date: | 2022 - 2024 |
| Title: | Glutamine Metabolism-targeted Therapeutics for Melanoma |
| Funding Source: | The University of Texas MD Anderson Cancer Center/NIH |
| Role: | PI |
| ID: | N/A |
| Date: | 2022 - 2027 |
| Title: | Interdisciplinary Translational Pre/Postdoctoral Program in Cancer Nanotechnology |
| Funding Source: | NIH/NCI |
| Role: | Mentor |
| ID: | T32CA196561 |
| Date: | 2022 - 2023 |
| Title: | Annotating Metabolic Vulnerabilities in Cholangiocarcinoma with Non-invasive PET Imaging |
| Funding Source: | The University of Texas MD Anderson Cancer Center/CCSG ROCIP Award |
| Role: | PI |
| ID: | N/A |
| Date: | 2021 - 2026 |
| Title: | EPHARNA: A non-coding RNA therapeutic for gynecologic cancers |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | u01CA268816 |
| Date: | 2021 - 2026 |
| Title: | Novel Radiolabeled Probes for Ovarian Cancer Imaging and Treatment |
| Funding Source: | UTRGV/NIH |
| Role: | PI |
| ID: | 1 R01 CA268732-01 |
| Date: | 2021 - 2023 |
| Title: | Novel PET Imaging to Guide Yttrium-90 Radioembolization Therapy in Hepatocellular Carcinoma |
| Funding Source: | MD Anderson Cancer Center SPORE in Hepatocellular Carcinoma |
| Role: | PI |
| Date: | 2021 - 2023 |
| Title: | Improved Staging and Metabolic Characterization via Quantitative PET Imaging xCT Activity in Pancreatic Ductal Adenocarcinoma (PDAC) Metastases |
| Funding Source: | UTMDACC GI SPORE DRP Program |
| Role: | PI |
| ID: | FP00013716 |
| Date: | 2020 - 2023 |
| Title: | STARs Award |
| Funding Source: | The University of Texas System Science & Technology Acquisition and Retention (STARs) Award |
| Role: | PI |
| Date: | 2020 - 2025 |
| Title: | Quantitative PET Imaging of Hepatocellular Carcinoma (HCC) |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01CA239694 |
| Date: | 2020 - 2024 |
| Title: | Effect of tumor cell glutamine metabolism on anti-tumor immunity in TNBC |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA250506 |
| Date: | 2020 - 2025 |
| Title: | CPRIT Recruitment - Established Investigator |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RR200046 |
| Date: | 2019 - 2024 |
| Title: | VUMC - SPORE in Breast Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | P50 CA098131 |
| Date: | 2019 - 2024 |
| Title: | Vanderbilt-Ingram Cancer Center SPORE in Gastrointestinal Cancer |
| Funding Source: | Vanderbilt University Medical Center / NIH / NCI |
| Role: | Principal Investigator-MDACC |
| ID: | P50CA236733 |
| Date: | 2019 - 2021 |
| Title: | General Electric Immuno-Oncology Center of Excellence |
| Funding Source: | General Electric |
| Role: | PI |
| ID: | M000X |
| Date: | 2019 - 2024 |
| Title: | VUMC - Quantitative PET Imaging to Predict Response to Inhibitors of Glutamine Metabolism in Colorectal Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01 CA242972 |
| Date: | 2019 - 2022 |
| Title: | VUMC - BC181155: Influence of Glutamine Metabolism in Tumor Microenvironment in TNBC |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | Co-I |
| ID: | BC181155 |
| Date: | 2019 - 2023 |
| Title: | Therapeutic Targeting of the Glutamine Transporter SLC1A5 in Advanced Prostate Cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| ID: | W81XWH-18-PCRP-IDA |
| Date: | 2019 - 2020 |
| Title: | VUMC - Development and evaluation of new ASCT2 inhibitors |
| Funding Source: | Dracen Pharmaceuticals |
| Role: | PI |
| ID: | M0050185 |
| Date: | 2019 - 2020 |
| Title: | VUMC - Evaluation of glutamine metabolism inhibitors; Study Phase 2 |
| Funding Source: | Dracen Pharmaceuticals |
| Role: | PI |
| ID: | M0050137 |
| Date: | 2019 - 2024 |
| Title: | VUMC - Influence of Glutamine Metabolism of Tumor Microenvironment in TNBC |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01 CA177681 |
| Date: | 2018 - 2020 |
| Title: | Pharmacological Inhibitors of Cancer Metabolism |
| Funding Source: | Dracen Pharmaceuticals |
| Role: | PI |
| Date: | 2018 - 2019 |
| Title: | VUMC - Evaluation of Glutamine Metabolism Inhibitors; Study Phase 1 |
| Funding Source: | Dracen Pharmaceuticals |
| Role: | PI |
| Date: | 2018 - 2025 |
| Title: | MDACC PREDICT |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | U24CA220325 |
| Date: | 2017 - 2022 |
| Title: | Hormonal, Metabolic and Signaling Interactions in PAH |
| Funding Source: | NIH/NHLBI |
| Role: | Co-I |
| ID: | P01 HL108800 |
| Date: | 2017 - 2022 |
| Title: | NextGen RNAi Delivery to Breast Tumors for Selective mTORC2 Blockade |
| Funding Source: | NIH/NIDDK |
| Role: | Co-I |
| ID: | R01CA224241 |
| Date: | 2017 - 2022 |
| Title: | Molecular and Cellular Basis for Digestive Diseases |
| Funding Source: | NIH/NIDDK |
| Role: | Preclinical Models of Digestive Disease Core Co-Director (Imaging) |
| ID: | P30 DK058404 |
| Date: | 2017 - 2019 |
| Title: | VUMC - Multimodal Immunoimaging for Screening Lung Cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | PI |
| Date: | 2016 - 2019 |
| Title: | VUMC - Imaging Activated Macrophages in the Lungs |
| Funding Source: | NIH/NHLBI |
| Role: | Co-PI |
| ID: | R01 HL131906 |
| Date: | 2016 - 2019 |
| Title: | VUMC - Targeting the Epithelial Type II Interleukin-4 Receptor in Metastatic Breast Cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| ID: | W81XWH-16-0569 |
| Date: | 2016 - 2017 |
| Title: | VUMC - A Simple and Effective Diagnostic Test for Gastrointestinal Bleeding to Improve Patient Outcomes |
| Funding Source: | NIH/NIDDK |
| Role: | PI |
| ID: | R41 DK106779 |
| Date: | 2016 - 2017 |
| Title: | VUMC - Roles for Lrig1 in Intestinal Neoplasia |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01 CA151566 |
| Date: | 2016 - 2017 |
| Title: | VUMC - Comprehensive Evaluation of OGSE DWI for Assessing Tumor Treatment Response |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01 CA173593 |
| Date: | 2016 - 2016 |
| Title: | VUMC - MRI Diffusion in Tumors Using Oscillating Gradients |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01 CA109106 |
| Date: | 2016 - 2016 |
| Title: | VUMC - Multidisciplinary Training in Basic and Translational Imaging of Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R25 CA092043 |
| Date: | 2016 - 2019 |
| Title: | VUMC - SPORE in Breast Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | P50 CA098131 |
| Date: | 2016 - 2020 |
| Title: | VUMC Cancer Center Support Grant |
| Funding Source: | NIH/NCI |
| Role: | Director of Cancer Imaging Research; Director of Animal and Human Imaging Shared Resource |
| ID: | P30 CA068485 |
| Date: | 2016 - 2017 |
| Title: | VUMC - Role of EGFR Ligand-containing Exosomes in Colorectal Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01 CA163563 |
| Date: | 2015 - 2016 |
| Title: | VUMC - Mouse Model of Invasive Colon Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R21 CA187307 |
| Date: | 2014 - 2016 |
| Title: | VUMC - Interventions Against the Molecular Etiology of BMPR2-induced PAH |
| Funding Source: | NIH/NHLBI |
| Role: | Co-I |
| ID: | R01 HL095797 |
| Date: | 2013 - 2016 |
| Title: | VUMC - Spore in Breast Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | P50 CA098131 |
| Date: | 2013 - 2016 |
| Title: | VUMC - Secreted RNA during CRC Progression: Biogenesis, Function and Clinical Markers |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | U19 CA179514 |
| Date: | 2013 - 2014 |
| Title: | VUMC - Novel PET Ligands to Image Pancreatic Cancer |
| Funding Source: | Lustgarten Foundation for Pancreatic Cancer Research |
| Role: | PI |
| ID: | 000 |
| Date: | 2012 - 2016 |
| Title: | VUMC - Comprehensive Evaluation of OGSE DWI for Assessing Tumor Treatment Response |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01 CA173593 |
| Date: | 2012 - 2015 |
| Title: | VUMC - Imaging Activated Macrophages in the Lungs |
| Funding Source: | NIH/NHLBI |
| Role: | Co-I |
| ID: | R01 HL116358 |
| Date: | 2012 - 2016 |
| Title: | VUMC - SPORE in GI Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | P50 CA095103 |
| Date: | 2012 - 2016 |
| Title: | VUMC - TSPO Ligands for Cancer Imaging |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01 CA163806 |
| Date: | 2012 - 2016 |
| Title: | VUMC - Molecular and Cellular Basis for Digestive Diseases |
| Funding Source: | NIH/NIDDK |
| Role: | Co-I |
| ID: | P30 DK058404 |
| Date: | 2012 - 2018 |
| Title: | VUMC - TSPO Ligands for Cancer Imaging |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01 CA163806 |
| Date: | 2012 - 2016 |
| Title: | VUMC - MRI Diffusion in Tumors Using Oscillating Gradients |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01 CA109106 |
| Date: | 2011 - 2016 |
| Title: | VUMC - Multidisciplinary Training in Basic and Translational Imaging of Cancer |
| Funding Source: | NIH/NIDDK |
| Role: | Co-I |
| ID: | R01 DK058587 |
| Date: | 2011 - 2015 |
| Title: | VUMC - Biological Basis of Imaging Biomarkers in Colorectal Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01 CA140628 |
| Date: | 2011 - 2012 |
| Title: | VUMC - Preclinical Tools for Cancer Imaging Research |
| Funding Source: | Licor Biosciences |
| Role: | PI |
| ID: | VUMC37860 |
| Date: | 2010 - 2016 |
| Title: | VUMC - Validation of Biomarkers of Risk for the Early Detection of Lung Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | U01 CA152662 |
| Date: | 2010 - 2011 |
| Title: | VUMC - Dedicated Quantitative Fluorescence Tomography System for Small Animal Imaging |
| Funding Source: | NIH/NCRR |
| Role: | PI |
| ID: | S10 RR027600 |
| Date: | 2009 - 2012 |
| Title: | VUMC - Molecular Determinants Affecting FLT-PET in Colorectal Cancer” |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | RC1 CA145138 |
| Date: | 2008 - 2014 |
| Title: | VUMC - Vanderbilt In Vivo Cellular and Molecular Imaging Center |
| Funding Source: | NIH/NCI |
| Role: | Project 1 Co-leader; Chemistry Core Leader |
| ID: | P50 CA128323 |
| Date: | 2008 - 2011 |
| Title: | VUMC - PET and SPECT Ligands for Imaging Neuronal Apoptosis |
| Funding Source: | NIH/NIMH |
| Role: | PI |
| ID: | R41MH85768 |
| Date: | 2008 - 2011 |
| Title: | VUMC - PET Imaging Biomarkers of IGF-1R Inhibition |
| Funding Source: | OSI Pharmaceuticals, Inc |
| Role: | PI |
| ID: | VUMC34293 |
| Date: | 2008 - 2013 |
| Title: | VUMC - Synergizing Quantitative HTS Technologies to Guide MIA Discovery and Development |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | K25 CA127349 |
| Date: | 2007 - 2008 |
| Title: | VUMC - VICC Breast Cancer Program |
| Funding Source: | NIH/NCI |
| Role: | Pilot Funding PI |
| ID: | P50CA098131 |
| Date: | 2007 - 2012 |
| Title: | VUMC - South-Eastern Center for Imaging Models of Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | U24 CA126588 |
| Date: | 2006 - 2008 |
| Title: | VUMC - Improved Characterization of Angiogenesis through Multi-Modality Imaging of VEGFR Expression and Tumor Physiology |
| Funding Source: | Vanderbilt University Medical Center |
| Role: | PI |
| Date: | 2006 - 2011 |
| Title: | VUMC - Effects of Tumors on the Skeleton |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | P01 CA040035 |
Selected Publications
Peer-Reviewed Articles
- Yamaguchi A, Yamazaki CM, Anami Y, Ha SYY, Xiong W, Ta RT, Zhang N, Manning HC, An Z, Tsuchikama K. 177Lu-Labeled Antibody-Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors. Mol Cancer Ther 24(6):907-919, 2025. e-Pub 2025. PMID: 40051166.
- Ciombor KK, Bae SW, Whisenant JG, Ayers GD, Sheng Q, Peterson TE, Smith GT, Lin K, Chowdhury S, Kanikarla Marie P, Sorokin A, Cohen AS, Goff LW, Cardin DB, Shen JP, Kopetz S, Eng C, Shyr Y, Berlin J, Manning HC. Results of the Phase I/II Study and Preliminary B-cell Gene Signature of Combined Inhibition of Glutamine Metabolism and EGFR in Colorectal Cancer. Clin Cancer Res 31(8):1437-1448, 2025. e-Pub 2025. PMID: 39927885.
- Ayers, GD, Cohen, A, Bae, SW, Wen, X, Pollard, AC, Sharma, S, Claus, T, Payne, AC, Geng, L, Zhao, P, Tantawy, MN, Gammon, ST, Manning, HC. Reproducibility and repeatability of 18F-(2S, 4R)-4-fluoroglutamine PET imaging in preclinical oncology models. PloS one 20(1), 2025. e-Pub 2025. PMID: 39787098.
- Lin, M, Pham, C, Ta, RT, Manning, HC. cGMP compliant one-step, one-pot automated [18F]FBnTP production for clinical imaging of mitochondrial activity. EJNMMI Radiopharmacy and Chemistry 9(1), 2024. e-Pub 2024. PMID: 38935218.
- Lin M, Ta RT, Manning HC. Simplified and highly-reliable automated production of [18F]FSPG for clinical studies. EJNMMI Radiopharm Chem 8(1):15, 2023. e-Pub 2023. PMID: 37486582.
- Moore, S, Quirk, JD, Lassiter, AW, Laforest, R, Ayers, GD, Badea, CT, Fedorov, A, Kinahan, PE, Holbrook, M, Larson, PE, Sriram, R, Chenevert, TL, Malyarenko, D, Kurhanewicz, J, Houghton, AG, Ross, B, Pickup, S, Gee, JC, Zhou, R, Gammon, ST, Manning, HC, Roudi, R, Daldrup-Link, HE, Lewis, MT, Rubin, D, Yankeelov, TE, Shoghi, KI. Co-Clinical Imaging Metadata Information (CIMI) for Cancer Research to Promote Open Science, Standardization, and Reproducibility in Preclinical Imaging. Tomography 9(3):995-1009, 2023. e-Pub 2023. PMID: 37218941.
- Gammon, ST, Cohen, A, Lehnert, AL, Sullivan, DC, Malyarenko, D, Manning, HC, Hormuth, DA, Daldrup-Link, HE, An, H, Quirk, JD, Shoghi, KI, Pagel, MD, Kinahan, PE, Miyaoka, RS, Houghton, AG, Lewis, MT, Larson, PE, Sriram, R, Blocker, SJ, Pickup, S, Badea, A, Badea, CT, Yankeelov, TE, Chenevert, TL. An Online Repository for Pre-Clinical Imaging Protocols (PIPs). Tomography 9(2):750-758, 2023. e-Pub 2023. PMID: 37104131.
- Peehl, DM, Badea CT, Chenevert TL, Daldrup-Link HE, Ding L, Dobrolecki LE, Houghton AM, Kinahan PE, Kurhanewicz J, Lewis MT, Li S, Luker GD, Ma CX, Manning HC, Mowery YM, O'Dwyer PJ, Pautler RG, Rosen MA, Roudi R, Ross BD, Shoghi KI, Sriram R, Talpaz M, Wahl, RL, Zhou R. Animal Models and Their Role in Imaging-Assisted Co-Clinical Trials. Tomography(9):657-680, 2023. e-Pub 2023.
- Gammon ST, Cohen AS, Lehnert AL, Sullivan D, Malyarenko D, Manning HC, Hormuth D, Daldrup-Link H, An H, Quirk JD, Shoghi K, Pagel MD, Kinahan PE, Miyaoka RS, Lewis MT, Larson P, Sriram R, Blocker SJ, Pickup S, Badea A, Badea CT, Chenevert TL. An Online Repository for Pre-clinical Imaging Protocols (PIPs). Tomography, 2023. PMID: 37104131.
- Bae SW, Wang J, Georgiou DK, Wen X, Cohen AS, Geng L, Tantawy MN, Manning HC. Feasibility of [18F]FSPG PET for Early Response Assessment to Combined Blockade of EGFR and Glutamine Metabolism in Wild-Type KRAS Colorectal Cancer. Tomography 9(2):497-508, 2023. e-Pub 2023. PMID: 36961000.
- Malyarenko D, Amouzandeh G, Pickup S, Zhou R, Manning HC, Gammon ST, Shoghi KI, Quirk JD, Sriram R, Larson P, Lewis MT, Pautler RG, Kinahan PE, Muzi M, Chenevert TL. Evaluation of Apparent Diffusion Coefficient Repeatability and Reproducibility for Preclinical MRIs Using Standardized Procedures and a Diffusion-Weighted Imaging Phantom. Tomography 9(1):375-386, 2023. e-Pub 2023. PMID: 36828382.
- Lin M, Coll RP, Cohen AS, Georgiou DK, Manning HC. PET Oncological Radiopharmaceuticals: Current Status and Perspectives. Molecules 27(20):6790, 2022. e-Pub 2022. PMID: 36296381.
- Wardak M, Sonni I, Fan AP, Minamimoto R, Jamali M, Hatami N, Zaharchuk G, Fischbein N, Nagpal S, Li G, Koglin N, Berndt M, Bullich S, Stephens AW, Dinkelborg LM, Abel T, Manning HC, Rosenberg J, Chin FT, Sam Gambhir S, Mittra ES. 18F-FSPG PET/CT Imaging of System xC- Transporter Activity in Patients with Primary and Metastatic Brain Tumors. Radiology 303(3):620-631, 2022. e-Pub 2022. PMID: 35191738.
- Paez R, Shah C, Cords AJ, Muterspaugh A, Helton JE, Antic S, Eisenberg R, Chen H, Grogan E, Manning HC, Walker RC, Mission PP. 18F-FSPG PET imaging for the evaluation of indeterminate pulmonary nodules. PLOS ONE 17(3):e0265427, 2022. e-Pub 2022. PMID: 35294486.
- Cohen AS, Grudzinski J, Smith GT, Peterson TE, Whisenant JG, Hickman TL, Kristen Ciombor KK, Cardin D, Eng C, Goff LW, Das S, Coffey RJ, Berlin JD, Manning HC. First-in-human PET imaging and estimated radiation dosimetry of L-[5-11C]-glutamine in patients with metastatic colorectal cancer. J Nucl Med 63(1):36-43, 2022. e-Pub 2021. PMID: 33931465.
- Zhang X, Liu F, Payne AC, Nickels ML, Bellan LM, Manning HC. Correction to: High-Yielding Radiosynthesis of [68 Ga]Ga-PSMA-11 Using a Low-Cost Microfluidic Device. Mol Imaging Biol 23(6):979, 2021. e-Pub 2021. PMID: 34338960.
- Jaggupilli A, Ly S, Nguyen K, Anand V, Yuan B, El-Dana F, Yan Y, Arvanitis Z, Piyarathna DWB, Putluri N, Piwnica-Worms H, Manning HC, Andreeff M, Battula VL. Metabolic stress induces GD2+ cancer stem cell-like phenotype in triple-negative breast cancer. British Journal of Cancer 126(4):615-627, 2021. e-Pub 2021. PMID: 34811508.
- Reinfeld BI, Madden MZ, Wolf MM, Chytil A, Bader JE, Patterson AR, Sugiura A, Cohen AS, Ali A, Do BT, Muir A, Lewis CA, Hongo RA, Young KL, Brown RE, Todd VM, Huffstater T, Abraham A, O'Neil RT, Wilson MH, Xin F, Tantawy MN, Merryman WD, Johnson RW, Williams CS, Mason EF, Mason FM, Beckermann KE, Vander Heiden MG, Manning HC, Rathmell JC, Rathmell WK. Cell-programmed nutrient partitioning in the tumour microenvironment. Nature 593(7858):282-288, 2021. e-Pub 2021. PMID: 33828302.
- Edwards DN, Ngwa VM, Raybuck AL, Wang S, Hwang Y, Kim LC, Cho SH, Paik Y, Wang Q, Zhang S, Manning HC, Rathmell JC, Cook RS, Boothby MR, Chen J. Selective glutamine metabolism inhibition in tumor cells improves anti-tumor T lymphocyte activity in triple-negative breast cancer. J Clin Invest 131(4):e140100, 2021. e-Pub 2021. PMID: 33320840.
- Cohen AS, Li J, Hight MR, McKinley ET, Fu A, Payne AC, Liu Y, Zhang D, Xie Q, Bai M, Ayers GD, Tantawy MN, Smith JA, Revetta F, Washington MK, Shi C, Merchant NB, Manning HC. TSPO-targeted PET and Optical Probes for the Detection and Localization of Pre-Malignant and Malignant Pancreatic Lesions. Clin Cancer Res 26(22):5914-5925, 2020. e-Pub 2020. PMID: 32933996.
- Zhang X, Liu F, Payne AC, Nickels ML, Bellan LM, Manning HC. High-Yielding Radiosynthesis of [68Ga]Ga-PSMA-11 Using a Low-Cost Microfluidic Device. Mol Imaging Biol 22(5):1370-1379, 2020. e-Pub 2020. PMID: 32632739.
- Cohen AS, Geng L, Zhao P, Fu A, Schulte ML, Graves-Deal R, Washington MK, Berlin J, Coffey RJ, Manning HC. Combined blockade of EGFR and glutamine metabolism in preclinical models of colorectal cancer. Transl Oncol 13(10):100828, 2020. e-Pub 2020. PMID: 32652471.
- Shoghi KI, Badea CT, Blocker SJ, Chenevert TL, Laforest R, Lewis MT, Luker GD, Manning HC, Marcus DS, Mowery YM, Pickup S, Richmond A, Ross BD, Vilgelm AE, Yankeelov TE, Zhou R. Co-Clinical Imaging Resource Program (CIRP): Bridging the Translational Divide to Advance Precision Medicine. Tomography 6(3):273-287, 2020. e-Pub 2020. PMID: 32879897.
- Buck, JR, Saleh S, Claus T, Lovly C, Hight MR, Nickels ML, Tantay MN, Manning HC. N-[18F]-Fluoroacetylcrizotinib: A Potentially Potent and Selective PET Tracer for Molecular Imaging of Non–small Cell Lung Cancer. Bio Org Med Chem Let 30(16), 2020. e-Pub 2020. PMID: 32631505.
- Knapp KA, Nickels ML, Manning HC. The Current Role of Microfluidics in Radiofluorination Chemistry. Mol Imaging Biol 22(3):463-475, 2020. e-Pub 2020. PMID: 31485889.
- Xia, Y, Ledwitch, K, Kuenze, G, Duran, A, Li, J, Sanders, CR, Manning, HC, Meiler, J. A unified structural model of the mammalian translocator protein (TSPO). Journal of Biomolecular NMR 73(6-7):347-364, 2019. e-Pub 2019. PMID: 31243635.
- Uddin MJ, Wilson AJ, Crews BC, Malerba P, Uddin MI, Kingsley PJ, Ghebreselasie K, Daniel CK, Nickels ML, Tantawy MN, Jashim E, Manning HC, Khabele D, Marnett LJ. Discovery of Furanone-Based Radiopharmaceuticals for Diagnostic Targeting of COX-1 in Ovarian Cancer. ACS Omega 4(5):9251-9261, 2019. e-Pub 2019. PMID: 31172046.
- Tang D, Li J, Nickels ML, Huang G, Cohen AS, Manning HC. Preclinical Evaluation of a Novel TSPO PET Ligand 2-(7-Butyl-2-(4-(2-[18F]Fluoroethoxy)phenyl)-5-Methylpyrazolo[1,5-a]Pyrimidin-3-yl)-N,N-Diethylacetamide (18F-VUIIS1018A) to Image Glioma. Mol Imaging Biol 21(1):113-121, 2019. e-Pub 2019. PMID: 29869061.
- Wang Y, Ayres KL, Goldman DA, Dickler MN, Bardia A, Mayer IA, Winer E, Fredrickson J, Arteaga CL, Baselga J, Manning HC, Mahmood U, Ulaner GA. Correction: 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials. Clin Cancer Res 25(4):1435, 2019. e-Pub 2019. PMID: 30770494.
- Joseph JD, Darimont B, Zhou W, Arrazate A, Young A, Ingalla E, Walter K, Blake RA, Nonomiya J, Guan Z, Kategaya L, Govek SP, Lai AG, Kahraman M, Brigham D, Sensintaffar J, Lu N, Shao G, Qian J, Grillot K, Moon M, Prudente R, Bischoff E, Lee KJ, Bonnefous C, Douglas KL, Julien JD, Nagasawa JY, Aparicio A, Kaufman J, Haley B, Giltnane JM, Wertz IE, Lackner MR, Nannini MA, Sampath D, Schwarz L, Manning HC, Tantawy MN, Arteaga CL, Heyman RA, Rix PJ, Friedman L, Smith ND, Metcalfe C, Hager JH. Correction: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer. Elife 8, 2019. e-Pub 2019. PMID: 30614786.
- Rosenberg AJ, Nickels ML, Schulte ML, Manning HC. Automated radiosynthesis of 5-[11C]l-glutamine, an important tracer for glutamine utilization. Nucl Med Biol 67:10-14, 2018. e-Pub 2018. PMID: 30359787.
- Smith CT, San Juan MD, Dang LC, Katz DT, Perkins SF, Burgess LL, Cowan RL, Manning HC, Nickels ML, Claassen DO, Samanez-Larkin GR, Zald DH. Ventral striatal dopamine transporter availability is associated with lower trait motor impulsivity in healthy adults. Transl Psychiatry 8(1):269, 2018. e-Pub 2018. PMID: 30531858.
- Okunieff P, Casey-Sawicki K, Lockney NA, Hoppe BS, Enderling H, Pinnix C, Welsh J, Krishnan S, Yothers G, Brown M, Knox S, Bristow R, Spellman P, Mitin T, Nabavizadeh N, Jaboin J, Manning HC, Feng F, Galbraith S, Solanki AA, Harkenrider MM, Tuli R, Decker RH, Finkelstein SE, Hsu CC, Ha CS, Jagsi R, Shumway D, Daly M, Wang TJC, Fitzgerald TJ, Laurie F, Marshall DT, Raben D, Constine L, Thomas CR, Kachnic LA. Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017. Clin Cancer Res 24(15):3500-3509, 2018. e-Pub 2018. PMID: 29661779.
- Zhang X, Liu F, Knapp KA, Nickels ML, Manning HC, Bellan LM. A simple microfluidic platform for rapid and efficient production of the radiotracer [18F]fallypride. Lab Chip 18(9):1369-1377, 2018. e-Pub 2018. PMID: 29658049.
- Tang D, Fujinaga M, Hatori A, Zhang Y, Yamasaki T, Xie L, Mori W, Kumata K, Liu J, Manning HC, Huang G, Zhang MR. Evaluation of the novel TSPO radiotracer 2-(7-butyl-2-(4-(2-([18F]fluoroethoxy)phenyl)-5-methylpyrazolo[1,5-a]pyrimidin-3-yl)-N,N-diethylacetamide in a preclinical model of neuroinflammation. Eur J Med Chem 150:1-8, 2018. e-Pub 2018. PMID: 29505933.
- Schulte ML, Fu A, Zhao P, Li J, Geng L, Smith ST, Kondo J, Coffey RJ, Johnson MO, Rathmell JC, Sharick JT, Skala MC, Smith JA, Berlin J, Washington MK, Nickels ML, Manning HC. Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models. Nat Med 24(2):194-202, 2018. e-Pub 2018. PMID: 29334372.
- Luo N, Nixon MJ, Gonzalez-Ericsson PI, Sanchez V, Opalenik SR, Li H, Zahnow CA, Nickels ML, Liu F, Tantawy MN, Sanders ME, Manning HC, Balko JM. DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Nat Commun 9(1):248, 2018. e-Pub 2018. PMID: 29339738.
- Magarik MA, Walker RC, Gilbert J, Manning HC, Massion PP. Intracardiac Metastases Detected by 18F-FSPG PET/CT. Clin Nucl Med 43(1):28-30, 2018. e-Pub 2018. PMID: 29076915.
- Zhang Q, Jeppesen DK, Higginbotham JN, Demory Beckler M, Poulin EJ, Walsh AJ, Skala MC, McKinley ET, Manning HC, Hight MR, Schulte ML, Watt KR, Ayers GD, Wolf MM, Andrejeva G, Rathmell JC, Franklin JL, Coffey RJ. Mutant KRAS Exosomes Alter the Metabolic State of Recipient Colonic Epithelial Cells. Cell Mol Gastroenterol Hepatol 5(4):627-629.e6, 2018. e-Pub 2018. PMID: 29930982.
- Tantawy MN, Manning HC, Peterson TE, Colvin DC, Gore JC, Lu W, Chen Z, Chad Quarles C. Translocator Protein PET Imaging in a Preclinical Prostate Cancer Model. Mol Imaging Biol 20(2):200-204, 2018. e-Pub 2018. PMID: 28822038.
- Tang D, Li J, Buck JR, Tantawy MN, Xia Y, Harp JM, Nickels ML, Meiler J, Manning HC. Evaluation of TSPO PET Ligands [18F]VUIIS1009A and [18F]VUIIS1009B: Tracers for Cancer Imaging. Mol Imaging Biol 19(4):578-588, 2017. e-Pub 2017. PMID: 27853987.
- Schulte ML, Hight MR, Ayers GD, Liu Q, Shyr Y, Washington MK, Manning HC. Non-Invasive Glutamine PET Reflects Pharmacological Inhibition of BRAFV600E In Vivo. Mol Imaging Biol 19(3):421-428, 2017. e-Pub 2017. PMID: 27770401.
- Wang Y, Ayres KL, Goldman DA, Dickler MN, Bardia A, Mayer IA, Winer E, Fredrickson J, Arteaga CL, Baselga J, Manning HC, Mahmood U, Ulaner GA. 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials. Clin Cancer Res 23(12):3053-3060, 2017. e-Pub 2017. PMID: 28011460.
- Li J, Smith JA, Dawson ES, Fu A, Nickels ML, Schulte ML, Manning HC. Optimized Translocator Protein Ligand for Optical Molecular Imaging and Screening. Bioconjug Chem 28(4):1016-1023, 2017. e-Pub 2017. PMID: 28156095.
- Xu J, Li K, Smith RA, Waterton JC, Zhao P, Ding Z, Does MD, Manning HC, Gore JC. A comparative assessment of preclinical chemotherapeutic response of tumors using quantitative non-Gaussian diffusion MRI. Magn Reson Imaging 37:195-202, 2017. e-Pub 2017. PMID: 27919785.
- Kavanaugh G, Williams J, Morris AS, Nickels ML, Walker R, Koglin N, Stephens AW, Washington MK, Geevarghese SK, Liu Q, Ayers D, Shyr Y, Manning HC. Utility of [18F]FSPG PET to Image Hepatocellular Carcinoma: First Clinical Evaluation in a US Population. Mol Imaging Biol 18(6):924-934, 2016. e-Pub 2016. PMID: 27677886.
- Osgood CL, Tantawy MN, Maloney N, Madaj ZB, Peck A, Boguslawski E, Jess J, Buck J, Winn ME, Manning HC, Grohar PJ. 18F-FLT Positron Emission Tomography (PET) is a Pharmacodynamic Marker for EWS-FLI1 Activity and Ewing Sarcoma. Sci Rep 6:33926, 2016. e-Pub 2016. PMID: 27671553.
- Qiao J, Grabowska MM, Forestier-Roman IS, Mirosevich J, Case TC, Chung DH, Cates JM, Matusik RJ, Manning HC, Jin R. Activation of GRP/GRP-R signaling contributes to castration-resistant prostate cancer progression. Oncotarget 7(38):61955-61969, 2016. e-Pub 2016. PMID: 27542219.
- Li J, Schulte ML, Nickels ML, Manning HC. New structure-activity relationships of N-acetamide substituted pyrazolopyrimidines as pharmacological ligands of TSPO. Bioorg Med Chem Lett 26(15):3472-7, 2016. e-Pub 2016. PMID: 27353534.
- Joseph JD, Darimont B, Zhou W, Arrazate A, Young A, Ingalla E, Walter K, Blake RA, Nonomiya J, Guan Z, Kategaya L, Govek SP, Lai AG, Kahraman M, Brigham D, Sensintaffar J, Lu N, Shao G, Qian J, Grillot K, Moon M, Prudente R, Bischoff E, Lee KJ, Bonnefous C, Douglas KL, Julien JD, Nagasawa JY, Aparicio A, Kaufman J, Haley B, Giltnane JM, Wertz IE, Lackner MR, Nannini MA, Sampath D, Schwarz L, Manning HC, Tantawy MN, Arteaga CL, Heyman RA, Rix PJ, Friedman L, Smith ND, Metcalfe C, Hager JH. The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer. Elife 5:e15828, 2016. e-Pub 2016. PMID: 27410477.
- Schulte ML, Khodadadi AB, Cuthbertson ML, Smith JA, Manning HC. 2-Amino-4-bis(aryloxybenzyl)aminobutanoic acids: A novel scaffold for inhibition of ASCT2-mediated glutamine transport. Bioorg Med Chem Lett 26(3):1044-1047, 2016. e-Pub 2016. PMID: 26750251.
- Hassanein M, Hight MR, Buck JR, Tantawy MN, Nickels ML, Hoeksema MD, Harris BK, Boyd K, Massion PP, Manning HC. Preclinical Evaluation of 4-[18F]Fluoroglutamine PET to Assess ASCT2 Expression in Lung Cancer. Mol Imaging Biol 18(1):18-23, 2016. e-Pub 2016. PMID: 25971659.
- Higginbotham JN, Zhang Q, Jeppesen DK, Scott AM, Manning HC, Ochieng J, Franklin JL, Coffey RJ. Identification and characterization of EGF receptor in individual exosomes by fluorescence-activated vesicle sorting. J Extracell Vesicles 5:29254, 2016. e-Pub 2016. PMID: 27345057.
- Han W, Zaynagetdinov R, Yull FE, Polosukhin VV, Gleaves LA, Tanjore H, Young LR, Peterson TE, Manning HC, Prince LS, Blackwell TS. Molecular imaging of folate receptor β-positive macrophages during acute lung inflammation. Am J Respir Cell Mol Biol 53(1):50-9, 2015. e-Pub 2015. PMID: 25375039.
- McKinley ET, Watchmaker JM, Chakravarthy AB, Meyerhardt JA, Engelman JA, Walker RC, Washington MK, Coffey RJ, Manning HC. [(18)F]-FLT PET to predict early response to neoadjuvant therapy in KRAS wild-type rectal cancer: a pilot study. Ann Nucl Med 29(6):535-42, 2015. e-Pub 2015. PMID: 25899481.
- Manning HC. World Molecular Imaging Congress 2015: precision medicine visualized. Mol Imaging Biol 17(3):295-6, 2015. e-Pub 2015. PMID: 25862478.
- Cheung YY, Nickels ML, McKinley ET, Buck JR, Manning HC. High-yielding, automated production of 3'-deoxy-3'-[(18)F]fluorothymidine using a modified Bioscan Coincidence FDG reaction module. Appl Radiat Isot 97:47-51, 2015. e-Pub 2015. PMID: 25531913.
- Whisenant JG, McIntyre JO, Peterson TE, Kang H, Sánchez V, Manning HC, Arteaga CL, Yankeelov TE. Utility of [18?F]FLT-PET to assess treatment response in trastuzumab-resistant and trastuzumab-sensitive HER2-overexpressing human breast cancer xenografts. Mol Imaging Biol 17(1):119-28, 2015. e-Pub 2015. PMID: 25034624.
- Schulte ML, Dawson ES, Saleh SA, Cuthbertson ML, Manning HC. 2-Substituted Nγ-glutamylanilides as novel probes of ASCT2 with improved potency. Bioorg Med Chem Lett 25(1):113-6, 2015. e-Pub 2015. PMID: 25435145.
- Buck JR, McKinley ET, Fu A, Abel TW, Thompson RC, Chambless L, Watchmaker JM, Harty JP, Cooper MK, Manning HC. Preclinical TSPO Ligand PET to Visualize Human Glioma Xenotransplants: A Preliminary Study. PLoS One 10(10):e0141659, 2015. e-Pub 2015. PMID: 26517124.
- Comerford SA, Huang Z, Du X, Wang Y, Cai L, Witkiewicz AK, Walters H, Tantawy MN, Fu A, Manning HC, Horton JD, Hammer RE, McKnight SL, Tu BP. Acetate dependence of tumors. Cell 159(7):1591-602, 2014. e-Pub 2014. PMID: 25525877.
- Tang D, Nickels ML, Tantawy MN, Buck JR, Manning HC. Preclinical imaging evaluation of novel TSPO-PET ligand 2-(5,7-Diethyl-2-(4-(2-[(18)F]fluoroethoxy)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)-N,N-diethylacetamide ([ (18)F]VUIIS1008) in glioma. Mol Imaging Biol 16(6):813-20, 2014. e-Pub 2014. PMID: 24845529.
- Cheung YY, Nickels ML, Tang D, Buck JR, Manning HC. Facile synthesis of SSR180575 and discovery of 7-chloro-N,N,5-trimethyl-4-oxo-3(6-[(18)F]fluoropyridin-2-yl)-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide, a potent pyridazinoindole ligand for PET imaging of TSPO in cancer. Bioorg Med Chem Lett 24(18):4466-4471, 2014. e-Pub 2014. PMID: 25172419.
- Powell AE, Vlacich G, Zhao ZY, McKinley ET, Washington MK, Manning HC, Coffey RJ. Inducible loss of one Apc allele in Lrig1-expressing progenitor cells results in multiple distal colonic tumors with features of familial adenomatous polyposis. Am J Physiol Gastrointest Liver Physiol 307(1):G16-23, 2014. e-Pub 2014. PMID: 24833705.
- Perrone MG, Malerba P, Uddin J, Vitale P, Panella A, Crews BC, Daniel CK, Ghebreselasie K, Nickels M, Tantawy MN, Manning HC, Marnett LJ, Scilimati A. PET radiotracer [¹8F]-P6 selectively targeting COX-1 as a novel biomarker in ovarian cancer: preliminary investigation. Eur J Med Chem 80:562-568, 2014. e-Pub 2014. PMID: 24832612.
- Hight MR, Cheung YY, Nickels ML, Dawson ES, Zhao P, Saleh S, Buck JR, Tang D, Washington MK, Coffey RJ, Manning HC. A peptide-based positron emission tomography probe for in vivo detection of caspase activity in apoptotic cells. Clin Cancer Res 20(8):2126-35, 2014. e-Pub 2014. PMID: 24573549.
- Uddin MI, Buck JR, Schulte ML, Tang D, Saleh SA, Cheung YY, Harp J, Manning HC. Microwave-assisted, one-pot reaction of 7-azaindoles and aldehydes: a facile route to novel di-7-azaindolylmethanes. Tetrahedron Lett 55(1), 2014. e-Pub 2014. PMID: 24396154.
- McKinley ET, Zhao P, Coffey RJ, Washington MK, Manning HC. 3'-Deoxy-3'-[18F]-Fluorothymidine PET imaging reflects PI3K-mTOR-mediated pro-survival response to targeted therapy in colorectal cancer. PLoS One 9(9):e108193, 2014. e-Pub 2014. PMID: 25247710.
- Goode GD, Ballard BR, Manning HC, Freeman ML, Kang Y, Eltom SE. Knockdown of aberrantly upregulated aryl hydrocarbon receptor reduces tumor growth and metastasis of MDA-MB-231 human breast cancer cell line. Int J Cancer 133(12):2769-80, 2013. e-Pub 2013. PMID: 23733406.
- Katsha A, Soutto M, Sehdev V, Peng D, Washington MK, Piazuelo MB, Tantawy MN, Manning HC, Lu P, Shyr Y, Ecsedy J, Belkhiri A, El-Rifai W. Aurora kinase A promotes inflammation and tumorigenesis in mice and human gastric neoplasia. Gastroenterology 145(6):1312-22.e1-8, 2013. e-Pub 2013. PMID: 23993973.
- Walsh AJ, Cook RS, Manning HC, Hicks DJ, Lafontant A, Arteaga CL, Skala MC. Optical metabolic imaging identifies glycolytic levels, subtypes, and early-treatment response in breast cancer. Cancer Res 73(20):6164-74, 2013. e-Pub 2013. PMID: 24130112.
- Xie J, Wang C, Virostko J, Manning HC, Pham W, Bauer J, Gore JC. A novel reporter system for molecular imaging and high-throughput screening of anticancer drugs. Chembiochem 14(12):1494-503, 2013. e-Pub 2013. PMID: 23881799.
- Tang D, McKinley ET, Hight MR, Uddin MI, Harp JM, Fu A, Nickels ML, Buck JR, Manning HC. Synthesis and structure-activity relationships of 5,6,7-substituted pyrazolopyrimidines: discovery of a novel TSPO PET ligand for cancer imaging. J Med Chem 56(8):3429-33, 2013. e-Pub 2013. PMID: 23521048.
- McKinley ET, Smith RA, Zhao P, Fu A, Saleh SA, Uddin MI, Washington MK, Coffey RJ, Manning HC. 3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer. J Nucl Med 54(3):424-30, 2013. e-Pub 2013. PMID: 23341544.
- McKinley ET, Liu H, McDonald WH, Luo W, Zhao P, Coffey RJ, Hanks SK, Manning HC. Global phosphotyrosine proteomics identifies PKCδ as a marker of responsiveness to Src inhibition in colorectal cancer. PLoS One 8(11):e80207, 2013. e-Pub 2013. PMID: 24260357.
- Thompson MM, Manning HC, Ellacott KL. Translocator protein 18 kDa (TSPO) is regulated in white and brown adipose tissue by obesity. PLoS One 8(11):e79980, 2013. e-Pub 2013. PMID: 24260329.
- Walsh AJ, Cook RS, Manning HC, Hicks DJ, Lafontant A, Arteaga CL, Skala MC. Autofluorescence Imaging Resolves Early Cancer Treatment Response In Vivo. Technical Digest (online)(Optical Society of America), 2013. e-Pub 2013.
- McKinley ET, Ayers GD, Smith RA, Saleh SA, Zhao P, Washington MK, Coffey RJ, Manning HC. Limits of [18F]-FLT PET as a biomarker of proliferation in oncology. PLoS One 8(3):e58938, 2013. e-Pub 2013. PMID: 23554961.
- McKinley ET, Smith RA, Tanksley JP, Washington MK, Walker R, Coffey RJ, Manning HC. [18F]FLT-PET to predict pharmacodynamic and clinical response to cetuximab therapy in Ménétrier's disease. Ann Nucl Med 26(9):757-63, 2012. e-Pub 2012. PMID: 22821337.
- Wang C, Xie J, Guo J, Manning HC, Gore JC, Guo N. Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer. Oncol Rep 28(4):1301-8, 2012. e-Pub 2012. PMID: 22895640.
- Buck JR, Saleh S, Uddin MI, Manning HC. Rapid, Microwave-Assisted Organic Synthesis of Selective (V600E)BRAF Inhibitors for Preclinical Cancer Research. Tetrahedron Lett 53(32):4161-4165, 2012. e-Pub 2012. PMID: 23180892.
- Wyatt SK, Manning HC, Bai M, Ehtesham M, Mapara KY, Thompson RC, Bornhop DJ. Preclinical molecular imaging of the translocator protein (TSPO) in a metastases model based on breast cancer xenografts propagated in the murine brain. Curr Mol Med 12(4):458-66, 2012. e-Pub 2012. PMID: 22348613.
- Myers MV, Manning HC, Coffey RJ, Liebler DC. Protein expression signatures for inhibition of epidermal growth factor receptor-mediated signaling. Mol Cell Proteomics 11(2):M111.015222, 2012. e-Pub 2012. PMID: 22147731.
- Tang D, Hight MR, McKinley ET, Fu A, Buck JR, Smith RA, Tantawy MN, Peterson TE, Colvin DC, Ansari MS, Nickels M, Manning HC. Quantitative preclinical imaging of TSPO expression in glioma using N,N-diethyl-2-(2-(4-(2-18F-fluoroethoxy)phenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide. J Nucl Med 53(2):287-94, 2012. e-Pub 2012. PMID: 22251555.
- Xu J, Li K, Smith RA, Waterton JC, Zhao P, Chen H, Does MD, Manning HC, Gore JC. Characterizing tumor response to chemotherapy at various length scales using temporal diffusion spectroscopy. PLoS One 7(7):e41714, 2012. e-Pub 2012. PMID: 22911846.
- Fox EM, Miller TW, Balko JM, Kuba MG, Sánchez V, Smith RA, Liu S, González-Angulo AM, Mills GB, Ye F, Shyr Y, Manning HC, Buck E, Arteaga CL. A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res 71(21):6773-84, 2011. e-Pub 2011. PMID: 21908557.
- Miller TW, Balko JM, Fox EM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, Jiang A, Smith RA, Maira SM, Manning HC, González-Angulo AM, Mills GB, Higham C, Chanthaphaychith S, Kuba MG, Miller WR, Shyr Y, Arteaga CL. ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov 1(4):338-51, 2011. e-Pub 2011. PMID: 22049316.
- McKinley ET, Bugaj JE, Zhao P, Guleryuz S, Mantis C, Gokhale PC, Wild R, Manning HC. 18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer. Clin Cancer Res 17(10):3332-40, 2011. e-Pub 2011. PMID: 21257723.
- Guo N, Xie J, Manning HC, Deane NG, Ansari MS, Coffey RJ, Gore J, Price RR, Baldwin RM, McIntyre JO. A novel in vitro assay to assess phosphorylation of 3'-[(18)F]fluoro-3'-deoxythymidine. Mol Imaging Biol 13(2):257-64, 2011. e-Pub 2011. PMID: 20532643.
- Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sánchez V, Chakrabarty A, Dave B, Cook RS, Pao W, McKinely E, Manning HC, Chang J, Arteaga CL. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci U S A 108(12):5021-6, 2011. e-Pub 2011. PMID: 21385943.
- Hight MR, Nolting DD, McKinley ET, Lander AD, Wyatt SK, Gonyea M, Zhao P, Manning HC. Multispectral fluorescence imaging to assess pH in biological specimens. J Biomed Opt 16(1):016007, 2011. e-Pub 2011. PMID: 21280913.
- Buck JR, McKinley ET, Hight MR, Fu A, Tang D, Smith RA, Tantawy MN, Peterson TE, Colvin D, Ansari MS, Baldwin RM, Zhao P, Guleryuz S, Manning HC. Quantitative, preclinical PET of translocator protein expression in glioma using 18F-N-fluoroacetyl-N-(2,5-dimethoxybenzyl)-2-phenoxyaniline. J Nucl Med 52(1):107-14, 2011. e-Pub 2011. PMID: 21149488.
- Tang D, Buck JR, Hight MR, Manning HC. Microwave-assisted Organic Synthesis of a High-affinity Pyrazolo-pyrimidinyl TSPO Ligand. Tetrahedron Lett 51(35):4595-4598, 2010. e-Pub 2010. PMID: 20689673.
- Wyatt SK, Manning HC, Bai M, Bailey SN, Gallant P, Ma G, McIntosh L, Bornhop DJ. Molecular imaging of the translocator protein (TSPO) in a pre-clinical model of breast cancer. Mol Imaging Biol 12(3):349-58, 2010. e-Pub 2010. PMID: 19949989.
- Ayers GD, McKinley ET, Zhao P, Fritz JM, Metry RE, Deal BC, Adlerz KM, Coffey RJ, Manning HC. Volume of preclinical xenograft tumors is more accurately assessed by ultrasound imaging than manual caliper measurements. J Ultrasound Med 29(6):891-901, 2010. e-Pub 2010. PMID: 20498463.
- Miller TW, Forbes JT, Shah C, Wyatt SK, Manning HC, Olivares MG, Sanchez V, Dugger TC, de Matos Granja N, Narasanna A, Cook RS, Kennedy JP, Lindsley CW, Arteaga CL. Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. Clin Cancer Res 15(23):7266-76, 2009. e-Pub 2009. PMID: 19934303.
- Sexton M, Woodruff G, Cudaback E, Kreitzer FR, Xu C, Lin YH, Möller T, Bai M, Manning HC, Bornhop D, Stella N. Binding of NIR-conPK and NIR-6T to astrocytomas and microglial cells: evidence for a protein related to TSPO. PLoS One 4(12):e8271, 2009. e-Pub 2009. PMID: 20020060.
- Yankeelov TE, Avison MJ, Damon BM, Manning HC, Peterson TE, Gore JC. Frontiers of Biomedical Imaging Science 2009: workshop report and research opportunities. Cancer Res 69(20):7902-4, 2009. e-Pub 2009. PMID: 19808955.
- Shah C, Miller TW, Wyatt SK, McKinley ET, Olivares MG, Sanchez V, Nolting DD, Buck JR, Zhao P, Ansari MS, Baldwin RM, Gore JC, Schiff R, Arteaga CL, Manning HC. Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. Clin Cancer Res 15(14):4712-21, 2009. e-Pub 2009. PMID: 19584166.
- Virostko J, Xie J, Hallahan DE, Arteaga CL, Gore JC, Manning HC. A molecular imaging paradigm to rapidly profile response to angiogenesis-directed therapy in small animals. Mol Imaging Biol 11(3):204-12, 2009. e-Pub 2009. PMID: 19130143.
- Manning HC, Shay SD, Mericle RA. Multispectral molecular imaging of capillary endothelium to facilitate preoperative endovascular brain mapping. J Neurosurg 110(5):975-80, 2009. e-Pub 2009. PMID: 19231927.
- Manning HC, Merchant NB, Foutch AC, Virostko JM, Wyatt SK, Shah C, McKinley ET, Xie J, Mutic NJ, Washington MK, LaFleur B, Tantawy MN, Peterson TE, Ansari MS, Baldwin RM, Rothenberg ML, Bornhop DJ, Gore JC, Coffey RJ. Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancer. Clin Cancer Res 14(22):7413-22, 2008. e-Pub 2008. PMID: 19010858.
- Manning HC, Lander A, McKinley E, Mutic NJ. Accelerating the development of novel molecular imaging probes: a role for high-throughput screening. J Nucl Med 49(9):1401-4, 2008. e-Pub 2008. PMID: 18703594.
- Manning HC. Optical imaging shines in vivo. Journal of Nuclear Medicine 49(1):23N-+, 2008. e-Pub 2008.
- Deane NG, Manning HC, Foutch AC, Washington MK, Aronow BJ, Aronow BA, Bornhop DJ, Coffey RJ. Targeted imaging of colonic tumors in smad3-/- mice discriminates cancer and inflammation. Mol Cancer Res 5(4):341-9, 2007. e-Pub 2007. PMID: 17426249.
- Manning HC, Shay SD, Santra S, Richter EO, Mericle RA. Endovascular Brain Mapping: An Intraoperative Strategy for Visualizing Functional Brain Parenchyma. Brain Research 1(4):217-34, 2007. e-Pub 2007.
- Manning HC, Smith SM, Sexton M, Haviland S, Bai M, Cederquist K, Stella N, Bornhop DJ. A peripheral benzodiazepine receptor targeted agent for in vitro imaging and screening. Bioconjug Chem 17(3):735-40, 2006. e-Pub 2006. PMID: 16704212.
- Smentek L, Hess BA, Cross JP, Manning HC, Bornhop DJ. Density-functional theory structures of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid complexes for ions across the lanthanide series. J Chem Phys 123(24), 2005. e-Pub 2005. PMID: 16396532.
- Manning HC, Bai MF, Anderson BM, Lisiak R, Samuelson LE, Bornhop DJ. Expeditious synthesis of 'P'-protected macrocycles en route to lanthanide chelate metal complexes. Tetrahedron letters 46(28):4707-10, 2005. e-Pub 2005.
- Manning HC, Goebel T, Thompson RC, Price RR, Lee H, Bornhop DJ. Targeted molecular imaging agents for cellular-scale bimodal imaging. Bioconjug Chem 15(6):1488-95, 2004. e-Pub 2004. PMID: 15546219.
- Manning HC, Skwierawska A, Marx JN, Bornhop DJ. Rapid removal of benzyloxycarbonyl groups from 1,4,7,10-tetraazacyclododecane derivatives by catalytic transfer hydrogenation. Synthetic Commun 33(3):457-61, 2003. e-Pub 2003.
- Manning HC, Goebel T, Marx JN, Bornhop DJ. Facile, efficient conjugation of a trifunctional lanthanide chelate to a peripheral benzodiazepine receptor ligand. Org Lett 4(7):1075-8, 2002. e-Pub 2002. PMID: 11922786.
- Griffin JMM, Skwierawska AM, Manning HC, Marx JN, Bornhop DJ. Simple, high yielding synthesis of trifunctional fluorescent lanthanide chelates. Tetrahedron letters 42(23):3823-5, 2001. e-Pub 2001.
Invited Articles
- Manning HC. Thymidine kinase 1 (TK1) regulation in oncology: impact on [18F]FLT PET as a cancer imaging biomarker. Society of Nuclear Medicine (SNM) Molecular Imaging Gateway 4(2):1-3, 2010. e-Pub 2010.
- Manning HC. Accelerating the development of novel molecular imaging probes: A role for high-throughput screening. Society of Nuclear Medicine (SNM) Molecular Imaging Gateway 2(1):1-4, 2008. e-Pub 2008.
- Manning HC. Molecular imaging: Images of Interest. Society of Nuclear Medicine (SNM) Molecular Imaging Gateway 1(1):5, 2007. e-Pub 2007.
- Manning HC, Foutch AC, Deane NG, Merchant N, Wyatt SK, Bai M, Bornhop DJ, Coffey RJ. A High-Throughput Molecular Imaging Screen to Monitor Therapeutic Response In Vivo. Cambridge Health Institute: Third annual “In Vivo Molecular Imaging, 2006. e-Pub 2006.
Review Articles
- Tran HH, Yamaguchi A, Manning HC. Radiotheranostic landscape: A review of clinical and preclinical development. Eur J Nucl Med Mol Imaging 52(7):2685-2709, 2025. e-Pub 2025. PMID: 39891713.
- Yamaguchi, A, Manning, HC. Diverse Roles of Antibodies in Antibody–Drug Conjugates. Pharmaceuticals 18(2), 2025. e-Pub 2025. PMID: 40005994.
- Pantel, A, Bae, SW, Li, EJ, O'Brien, SR, Manning, HC. PET Imaging of Metabolism, Perfusion, and Hypoxia. Cancer Journal (United States) 30(3):159-169, 2024. e-Pub 2024. PMID: 38753750.
- Coll RP, Bright SJ, Martinus DKJ, Georgiou DK, Sawakuchi GO, Manning HC. Alpha Particle-Emitting Radiopharmaceuticals as Cancer Therapy: Biological Basis, Current Status, and Future Outlook for Therapeutics Discovery. Mol Imaging Biol 25(6):991-1019, 2023. e-Pub 2023. PMID: 37845582.
- Peehl, DM, Badea, CT, Chenevert, TL, Daldrup-Link, HE, Ding, L, Dobrolecki, LE, Houghton, AG, Kinahan, PE, Kurhanewicz, J, Lewis, MT, Li, S, Luker, GD, Ma, C, Manning, HC, Mowery, YM, O’Dwyer, PJ, Pautler, RG, Rosen, M, Roudi, R, Ross, B, Shoghi, KI, Sriram, R, Talpaz, M, Wahl, RL, Zhou, R. Animal Models and Their Role in Imaging-Assisted Co-Clinical Trials. Tomography 9(2):657-680, 2023. e-Pub 2023. PMID: 36961012.
- Manning HC, Buck JR, Cook RS. Mouse Models of Breast Cancer: Platforms for Discovering Precision Imaging Diagnostics and Future Cancer Medicine. J Nucl Med 57 Suppl 1:60S-8S, 2016. e-Pub 2016. PMID: 26834104.
- Yankeelov TE, Peterson TE, Abramson RG, Izquierdo-Garcia D, Arlinghaus LR, Li X, Atuegwu NC, Catana C, Manning HC, Fayad ZA, Gore JC. Simultaneous PET-MRI in oncology: a solution looking for a problem?. Magn Reson Imaging 30(9):1342-56, 2012. e-Pub 2012. PMID: 22795930.
- Gore JC, Manning HC, Quarles CC, Waddell KW, Yankeelov TE. Magnetic resonance in the era of molecular imaging of cancer. Magn Reson Imaging 29(5):587-600, 2011. e-Pub 2011. PMID: 21524870.
- Smith RA, Guleryuz S, Manning HC. Molecular imaging metrics to evaluate response to preclinical therapeutic regimens. Front Biosci (Landmark Ed) 16(2):393-410, 2011. e-Pub 2011. PMID: 21196177.
- Peterson TE, Manning HC. Molecular imaging: 18F-FDG PET and a whole lot more. J Nucl Med Technol 37(3):151-61, 2009. e-Pub 2009. PMID: 19692452.
Editorials
- Manning, HC. Passing the Molecular Imaging and Biology Torch. Molecular Imaging and Biology 26(2):189-190, 2024. PMID: 38512546.
Abstracts
- Shilpa Sharma, Denise Hernandez, Xiaoxia Wen, Jianbo Wang, Cong-Dat Pham, Beibei Huang, Manning HC. TSPO-targeted near-infrared optical probe for early identification and localization of high-risk premalignant pancreatic lesions. Proceedings of the American Association for Cancer Research Annual Meeting 2024. e-Pub 2024.
- Malyarenko D, Amouzandeh G, Pickup S, Zhou R, Manning HC, Gammon ST, Shoghi KI, Quirk JD, Sriram R, Larson P, Lewis MT, Pautler RG, Kinahan PE, Muzi M, Chenevert TL. ADC Repeatability and Reproducibility of NCI CIRP Network Pre-Clinical MRIs. ISMRM Annual Meeting June 03-08, 2023, 2022. e-Pub 2022.
- Coll R, Manning HC. Overexpressed transmembrane glycoprotein MUC13 is targeted by a zirconium-89 radiolabeled antibody as viewed by PET imaging in a colorectal cancer xenograft mouse model. WMIC 2022 - World Molecular Imaging Congress, 2022. e-Pub 2022.
- Bae SW, Manning HC. Preclinical Evaluation of 4-[18F]Fluoroglutamine PET predicts response to combined Inhibition of EGFR and glutaminolysis in KRAS wild-type metastatic colorectal cancer. WMIC 2022 - World Molecular Imaging Congress, 2022. e-Pub 2022.
- Pham CD, Manning HC. Synthesis Methodology Towards Novel ASCT2 Inhibitors. 2022 CSI Spring Retreat, 2022. e-Pub 2022.
- Coll R, Manning HC. A Study in Targeting Epithelial Carcinomas Using a 89Zr-Radiolabeled Anti-MUC13 Antibody. 2022 CSI Spring Retreat, 2022. e-Pub 2022.
- Bae SW, Manning HC. Feasibility of PET imaging for predicting response to combined Inhibition of EGFR and glutaminolysis in KRAS WT CRC. 2022 CSI Spring Retreat, 2022. e-Pub 2022.
- Wang JB, Manning HC. Screening the Potential Best Candidate of Small Molecule Inhibitors of Cancer Metabolism. 2022 CSI Spring Retreat, 2022. e-Pub 2022.
- Wen XX, Manning HC. Detection of HCC Tumors by 18F-FSPG PET in High-Fat-Diet Fed MUP-µPA Transgenic Mouse Model. 2022 CSI Spring Retreat, 2022. e-Pub 2022.
- Paez R, Shah C, Connelly CC, Myczkowski C, Muterspaugh A, Helton T, Manning HC, Smith G, Walker RC, Massion PP. 18F-FSPG PET imaging for the evaluation of indeterminate pulmonary nodules. American Thoracic Society Conference, 2020. e-Pub 2020.
- Marcu L, Vernier PT, Manning HC, Salemi S, Li A, Craft CM, Gundersen MA, Bornhop D. Fluorescence microscopy studies of a peripheral-benzodiazepine-receptor-targeted molecular probe for brain tumor imaging. Proceedings of SPIE-The International Society for Optical Engineering:64-9. e-Pub 2003.
- Manning HC, Goebel T, Bornhop DJ. Synthesis and Physical Spectroscopy of Lanthanide Chelates as Contrast Agents. Photonics West (The International Society for Optical Engineering: SPIE), 2002. e-Pub 2002.
- Manning HC, Goebel TS, Weigel M, Bornhop DJ. Lanthanide Chelates as Multi-Use Molecular Imaging Agents. The International Society for Optical Engineering (SPIE), 2002. e-Pub 2002.
Book Chapters
- Buck JR, Hight MR, Tang D, Manning HC. Contrast agents for T1-weighted MRI. In: Quantitative MRI in Cancer. CRC Press, Imaging in Medical Diagnosis and Therapy Series, 2011.
- Gore JC, Manning HC, Peterson TE, Quarles CC, Sinha TK, Yankeelov T. Quantitative Imaging Biomarkers of Cancer. In: Advances in Medical Physics. Medical Physics Publishing, 2010.
- Manning HC, Wyatt SK, Goebel TS, Griffin JM, Kiefer G, Motamedi M, Bell B, Thompson RC, Ehtesham M, Cederquist K, Bornhop DJ. Lanthanide Complexes as Optical Imaging Agents. In: Recent Advances of Bioconjugate Chemistry in Molecular Imaging. Research Signpost, 283-307, 2008.
- Gore JC, Joers JM, Manning HC, Kennan RP. Contrast Agents and Relaxation Effects. In: MRI of the Brain and Spine. 4th. Lippincott Williams & Wilkins, 2008.
Patents
- Manning H, Schulte M. Metabolism probes for therapy and diagnosis. Patent Number: 10189805.
- Hight H. Compound, composition, and method for detecting caspase activity and/or apoptosis. Patent Number: 10294271.
- Bornhop DJ, Manning H, Bai M, Wyatt SK. Agents for therapy efficacy monitoring and deep tissue imaging. Patent Number: 8188116.
- Bornhop DJ, Manning H, Bai M, Sinha SW. Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging. Patent Number: 8841320.
- Bornhop DJ, Manning H, Goebel T. Multi-use multimodal imaging chelates. Patent Number: 7338651.
- Bornhop DJ, Manning H, Goebel T. Multi-use multimodal imaging chelates. Patent Number: 8323621.
- Bornhop DJ, Manning H, Bai M, Wyatt SK. Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging. Patent Number: 8372868.
- Bornhop DJ, Manning H, Bai M, Wyatt SK. Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging. Patent Number: 7754884.
- Manning H, Buck JR, Tang D. TSPO ligands for cancer imaging and treatment. Patent Number: 9458161.
CV information above last modified July 31, 2025
Request an Appointment
Whether you are ready to make an appointment now or have questions for our expert team, we are standing by to help.
Related Links
Clinical Trials
Our patients have access to clinical trials offering promising new treatments that cannot be found anywhere else.